No retraction, correction or concern found when last checked on Oct 19, 2026.

Kaempferol: Antimicrobial Properties, Sources, Clinical, and Traditional Applications

Argyrios Periferakis, Konstantinos Periferakis, Ioana Anca Badarau and 7 more

International Journal of Molecular Sciences · 2022 · Review · CC BY

Abstract

Flavonoids are a category of plant-derived compounds which exhibit a large number of health-related effects. One of the most well-known and studied flavonoids is kaempferol, which can be found in a wide variety of herbs and plant families. Apart from their anticarcinogenic and anti-inflammatory effects, kaempferol and its associated compounds also exhibit antibacterial, antifungal, and antiprotozoal activities. The development of drugs and treatment schemes based on these compounds is becoming increasingly important in the face of emerging resistance of numerous pathogens as well as complex molecular interactions between various drug therapies. In addition, many of the kaempferol-containing plants are used in traditional systems all over the world for centuries to treat numerous conditions. Due to its variety of sources and associated compounds, some molecular mechanisms of kaempferol antimicrobial activity are well known while others are still under analysis. This paper thoroughly documents the vegetal and food sources of kaempferol as well as the most recent and significant studies regarding its antimicrobial applications.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

1In general, natural substances have been a recent target of research for their numerous health benefits and also for their potential as the basis for new drugs. The use of plants and herbs is documented by numerous authors both in Europe and elsewhere. The aim of such research is two-pronged, both to explore new opportunities for effective therapeutical agents, and also to elucidate the correlation between a decreased incidence of health problems and the consumption of certain food types. Regarding this last aim, it is the logical course of action, since certain diets are correlated with negative mortality and morbidity incidence rates—in addition, based on the research of specific diet choices after the diagnosis of cancer may improve survival rates.

2The focus of this paper is kaempferol, (3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one), a flavonoid with many promising health benefits found in a variety of plants. Kaempferol is named in honor of Engelbert Kaempfer, a German doctor, naturalist, and historian who lived during the 17th century and made a significant contribution to transporting medical knowledge from Japan to the West. Kaempferol, as a chemical compound, was discovered in Camelia sinensis (tea tree) and exhibits a host of different positive health-related effects.

3In this review, we will present a thorough view of the studies which have aimed to ascertain the use of kaempferol against pathogens, namely protozoa, fungi and bacteria, describing the molecular mechanisms of action, where literature data is available. We will also explain the relative importance of the pathogens described to justify the importance of the studies on kaempferol as a novel basis for therapies and drug design. A number of these researches have focused on the extracts of plants that are included in traditional medical systems in different countries and regions. Accordingly, we will also describe the traditional use of kaempferol-containing plants and we will also present the most prominent plant species which contain kaempferol in regard to biosynthesis and availability of the substance.

2. Biosynthesis and Availability of Kaempferol

4Kaempferol is a flavonoid; flavonoids are regarded as the largest group of secondary plant metabolites. They are polyphenolic compounds of low molecular weight and are used by plants to stimulate and regulate their growth and for defense purposes. Flavonoids are divided into a number of groups based on their chemical composition, namely flavones, flavonols, flavanones, isoflavonoids, neoflavonoids, catechins (flavanols), anthocyanins and chalcones. The antioxidant properties of polyphenols—flavonoids are such compounds—are already well known; more than 104 types of flavonoids are estimated to exist. Other proven effects of flavonoids include hepatoprotective, antimicrobial, renoprotective, antidiabetic, cardioprotective, anti-arthritic, neuroprotective, gastroprotective and anti-mutagenic, among others.

5Recently, there has been an increasing amount of research interest in the anti-carcinogenic potential of kaempferol, as a positive correlation between its consumption and reduced cancer incidence has been documented; this is in addition to existing epidemiological studies linking increased flavonoid consumption with reduced cancer incidence. The anti-inflammatory role of kaempferol has also been concisely presented by, while even its anti-adipogenic potential has come under investigation.

6The basic structure of all flavonoids, regardless of their subclass, is a 15-carbon benopyranone or benzopyran in which the three-carbon bridge between the phenyl groups is commonly cyclized with oxygen forming a C6-C3-C6 flavan nucleus.

7Kaempferol is specifically classified as a flavonol and has the molecular formula C15H10O6 (Figure 1).

2.1. Biosynthetic Pathways of Kaempferol

8Flavonoids are synthetized via the shikimic acid pathway, a process that occurs in the plants’ plastids. More than 2000 compounds are known, with nearly 500 occurring in a free-aglycone state and the rest as O- or C-glycosides. Flavonols, in their free forms as aglycones, have lipophilic properties, yet most flavonols produced in plants are attached to a sugar moiety, the glycoside form, and are water-soluble. The hydroxyl functional groups present in each flavonol are potential sites for linkage to saccharides as O-glycosides. The saccharides most commonly attached to flavonols are monosaccharides such as glucose, rhamnose, galactose, arabinose, and xylose, and the disaccharide rutinose (glucose and rhamnose connected by a β-glycosidic bond).

2.2. Bioavailability of Kaempferol

9The pharmacokinetics of kaempferol has been studied in vitro and in vivo, both in rats and humans. Flavonols such as kaempferol are commonly ingested as glycosides. The types and attachments of saccharide impact bioavailability, and also bioactivity.

10Glycosides are highly polar compounds, a property that greatly impacts their absorption, whereas the intermediate polarity of aglycones facilitates it. For some types of glycosides, previous hydrolysis to absorbable aglycones is needed, and others can be absorbed without hydrolysis.

11Like other flavonoids, kaempferol is mainly absorbed in the small intestine. The lipophilicity of aglycone kaempferol facilitates its absorption by passive diffusion, but evidence suggests that it can also be absorbed by facilitated diffusion or active transport. The nature of sugar linking will influence the compound uptake, as enterocytes have a preference for glucose, as membrane-bound beta-glucosidase breaks down the glucoside before absorption. Kaempferol glucosides with many sugar units in their structure travel to the large intestine, where gut microbiota will remove terminal saccharides exposing the glucose, and then absorption by enterocytes occurs. Studies have shown that kaempferol-O-glycosides decomposition can be extended to a breakdown process known as C-ring fission (C-ring is the central ring of the flavonoid structure) to form simple phenolic compounds such as 4-hydroxyphenylacetic acid, phloroglucinol and 4- methylphenol, which can either be absorbed or excreted in feces.

12After absorption, conjugated forms of kaempferol, some phenolic compounds produced by the colon microflora, kaempferol, and some kaempferol glycosides can reach systemic circulation and tissues and are transported along with intestinal metabolites to the liver, where a part of them are metabolized (mainly compounds with poor hydro solubility). In the liver, and also in enterocytes, metabolism involves the phase I (oxidation and O-demethylation) and the phase II pathway (sulfation, glucuronidation, and methylation) followed by distribution to body tissues and urine excretion.

13Pure kaempferol can be isolated from several plant species (Table 1), in the Divisions Pteridophyta, Coniferophyta, and Angiosperms of the Kingdom Plantae. In addition, the glycosides of kaempferol can be identified in many plant families—a detailed account of the various kaempferol chemical compounds and derivatives may be found in recent studies. The kaempferol content of some common foodstuffs is provided in Table 2.

3. Kaempferol as an Antibacterial Agent

14The antibacterial properties of the secondary metabolites of plants have been in the foreground of research in the last two decades. Such research is even more important considering the emergence of numerous resistant and multi-drug resistant (MRD) bacteria. Kaempferol-containing extracts and preparations, as well as pure kaempferol compounds, have been tested as possible antibacterials for quite some time.

15The investigation into the action mechanisms behind the antibacterial activity of kaempferol has proven difficult due to the large variety within the family of kaempferol derivatives but also due to the diversity in morphology and functions between the numerous species of bacteria. However, some theories have been advanced and validated regarding the potential action mechanisms in specific bacteria. For instance, have shown that a mixture of kaempferol 3-O-b-(200-acetyl) galactopyranoside and quercetin exerts antibacterial effects through cell membrane disruption, followed by activation of apoptosis and DNA fragmentation in M. luteus cells. Kaempferol was also the most effective tested flavonoid in damaging the cell membrane of Escherichia coli in a study by, where the findings were objectified by showing bacterial protein leakage into the extracellular environment. Moreover, kaempferol and quercetin interact with 3-oxyacyl-[acyl carrier protein] reductase (FabG) and enoyl-acyl carrier protein reductase therefore inhibiting the biosynthesis of fatty acids by Mycobacterium, Pseudomonas aeruginosa, and Vibrio cholerae thus hindering the function of the cell envelope as well as the impeding creation of bacterial biofilms. Another important antibacterial mechanism was demonstrated for E. coli, where kaempferol was shown to be the most effective flavonoid in directly inhibiting the bacterial DNA gyrase; similarly, kaempferol inhibited the DNA gyrase in methicillin-resistant Staphylococcus aureus. Kaempferol was also able to inhibit DNA helicases, more specifically SAPriA in Staphylococcus aureus, as shown by.

16Actions of kaempferol compounds against Porphyromonas gingivalis, Prevotella intermedia, and Cutibacterium acnes have been described by. The research of had already indicated the antibacterial effect of the extract of S. hymettia against Enterobacter cloacae, and also other bacteria, as will be presented below. The extract of Helichrysum compactum, which contained pure kaempferol and also kaempferol-3-O-glucoside, proved to have a degree of antibacterial activity. It is also possible, that the extract from Nephelium lappaceum, which contains kaempferol compounds, has antimicrobial activity. A local Malaysian herb, kacip Fatimah, i.e., the plant Labisa pumila Benth, which contains kaempferol, was found to have some antibacterial activity against Micrococcus luteus, Bacillus subtillis, Bacillus cereus, Staphylococcus aureus, Enterobacter aerogenes, Klebsiella pneumoniae, Escherichia coli and Pseudomonas aeruginosa, albeit at relatively low bacterial loads. The extract of Uapaca heudelotti proved effective against S. pneumoniae, as well as against other pathogens. It is also important to note that while some kaempferol-containing extracts may not have significant antibacterial action on their own, they may potentiate the action of some antibiotics.

17Subsequently, we will present the most important research on the antimicrobial activities of kaempferol against different bacterial genera (Table 3), which are human pathogens of particular interest.

3.1. Antibacterial Activity against Acinetobacter baumannii

18This coccobacillus was once considered of low importance, from a medical standpoint, but has now emerged as a prominent healthcare unit-acquired and community-acquired infection. It frequently causes pulmonary infections and septicemia in immunocompromised patients. Its antibiotic resistance and increased survival in harsh environments further enhance its pathogenicity. At the moment, the results of the kaempferol-containing compounds against this pathogen are quite promising, and this can be important in the face of ever-increasing antibiotic resistance.

19The compound kaempferol-3,7-O-α-l-dirhamnoside was found to be moderately inhibitory against A. baumannii. A novel nanotechnology application involving a blend loaded with kaempferol nanocrystals showed very promising results against A. baumannii; the research focused on treating infected wounds. Kaempferol-containing propolis extracts have also proved effective against A. baumannii in vitro. The action of a further kaempferol-containing compound, the extract of Geranium ibericum subsp. jubatum, was also found to be almost as effective as some commercial antibiotics against this pathogen in vitro. Earlier research indicated that the kaempferol-containing extract of K. fedtschenkoi was effective against this pathogen.

3.2. Antibacterial Activity against Bacillus Spp.

20In general, the bacteria of this genus are aerobic (; and references therein), rod-shaped bacteria, which are spore-forming and resistant to disinfectants and harsh environmental conditions. According to, only a handful of species from this genus are pathogenic; although current research has focused on the antibacterial actions of kaempferol against B. subtilis, which is non-pathogenic, the existing research experience can be potentially used in the future to find effective antimicrobial phytochemicals against the pathogenic bacillus species, namely B. anthracis and B. cereus.

21An extract of taif’s rose (Rosa damascena Mill. var. trigintipetala) exhibited antimicrobial activity against B. subtilis as well as other microorganisms. The extract contained kaempferol amongst other compounds. Earlier research by indicated that the antibacterial action of kaempferol-3,7-O-α-l-dirhamnoside, on its own, was quite moderate. The fermented aerial part of Bupleurum chinense also contains kaempferol and exhibited promising antibacterial action against this bacterium. The compound kaempferol-3-O-glucoside, which was isolated from the stem bark of Uapaca heudelotti, was also effective in that regard.

22Based on the research of, the kaempferol compounds of the extract of Buddleja indica Lam. enable it to act as a local antiseptic, effective against B. subtilis. The novel research of on the extract of Astragalus creticus, which, among other compounds, contains kaempferol and kaempferol-7-O-β-D-glucopyranose, proved their efficacy against this pathogen. Finally, the conjugation of kaempferol with silver nanoparticles proved effective against B. subtilis.

3.3. Antibacterial Activity against Escherichia coli

23These bacteria are physiological colonizers of the gastrointestinal tract; the colonization begins typically shortly after birth. They typically do not cause disease in immunocompetent patients but will become pathogenetic, if they migrate to other locations or if their host becomes immunocompromised. The most well-described E. coli pathogenic categories are the enteropathogenic E. coli (EPEC), the enterohaemorrhagic E. coli (EHEC), the enterotoxigenic E. coli (ETEC), the enteroaggregative E. coli (EAEC), the enteroinvasive E. coli (EIEC) and the diffusely adherent E. coli (DAEC). Commonly, E. coli infections are centered around the gastrointestinal and urogenital systems. Although most such infections can be easily treated, the emergence of multi-drug resistant (MDR) E. coli presents a novel therapeutical challenge.

24The anti-microbial action of kaempferol-3,7-O-α-l-dirhamnoside was moderate against E. coli. Success in that regard was also documented by who used the extract of S. hymettia. The extract of B. chinense, which contained kaempferol-3-O-β-D-rutinoside and kaempferol proved effective against this bacterium. The propolis extracts studied by were also found to be effective against this pathogen. The combination of kaempferol with silver nanoparticles was also proven to be effective against E. coli. The phytochemical extracts of also proved effective against E. coli.

3.4. Antibacterial Activity against Klebsiella pneumoniae

25Klebsiella pneumoniae represents an important human opportunistic pathogen and an emerging concern in clinical settings. It accounts for virtually one-third of the total Gram-negative bacterial infections. Klebsiella infections, especially in nosocomial settings, are rather severe. The emergence of K. pneumoniae strains which are resistant to even last-line antibiotics means that is not improbable, in the near future, that new compounds, whether natural or artificial, will be required to counter it. Interestingly, a strain of Klebsiella was found to even be resistant to chlorine treatment in water.

26The anti-microbial action of kaempferol-3,7-O-α-l-dirhamnoside, was moderately effective against K. pneumoniae. A similar anti-Klebsiella activity was also found by. Earlier research by, on the extract of Argyreia speciosa, which was determined to contain kaempferol 7-O-methyl-3-sulphate, showed that it was inhibitory for K. pneumoniae growth. Similar successful antibacterial action was documented by, who used the extract of S. hymettia. The extract studied by proved to also be effective against K. pneumoniae, as well as the extract studied by.

3.5. Antibacterial Activity against Mycobacterium Spp.

27From the Mycobacterium genus, the most well-known and dangerous pathogen is Mycobacterium tuberculosis, which is the causative agent of tuberculosis, one of the oldest human diseases. Although a vaccine against the disease exists, it is of varying efficiency and has proven incapable of stopping the global epidemic. While there exist antibiotics effective against tuberculosis during the last few years, the increase in antibiotic resistance of M. tuberculosis has led to the emergence of multi (MDR), extensively (XDR), extremely (XXDR) and total (TDR) drug-resistant strains; these are estimated to kill about 75 · 106 people, in the next three decades. Although resistance-conferring mutations may reduce the overall fitness of the bacteria, it has been suggested by that the resistant bacteria may find ways to circumvent this limitation. Thus, it is evident that tuberculosis may again come to the foreground as a major disease, even in Western countries. M. bovis infects primarily cattle but can also spread to humans; however, it is not of particular importance as a human pathogen. Rather, its study is of interest in understanding the pathogenetic mechanism of M. tuberculosis.

28Based on the research of, a leaf and hardwood extract from Vatairea macrocarpa, a plant used in Brazilian folk medicine, exhibited antibacterial action, in an in vivo model, in rat paws infected with M. bovis. The action of kaempferol-3-O-rhamnopyranoside was supplemented by that of other flavonoids in the extract. The extract was also found to have significant anti-inflammatory parameters.

29The extract of Argyreia speciosa was found to have antibacterial properties against M. tuberculosis. Another medicinal plant, Doliocarpus dentatus, proved to be effective in a rat model, as an antimycobacterial agent; the phenolic extract of its leaves contains kaempferol 3-O-α-L-rhamnopyranoside. The extract of Pluchea indica, which contained kaempferol, was identified as a potent inhibitor of the M. tuberculosis CYP121 in a recent study by. Finally, pure kaempferol from Bauhinia vahlii, was found, along with other flavonols, to be effective against M. tuberculosis.

3.6. Antibacterial Activity against Pseudomonas aeruginosa

30This is a versatile opportunistic pathogen, from a metabolic point of view, which can cause both localized and systemic infections in humans, of varying degrees of severity; recently, it has come to the foreground as a potent causative agent of nosocomial infections. People already suffering from cystic fibrosis and COPD are at an increased risk of contracting P. aeruginosa, even outside of healthcare units. It is of particular note that in cystic fibrosis patients, the bacterium may persist for decades. Although some of the P. aeruginosa infections are relatively easily treated, other cases are still characterized by increased morbidity and mortality. It has been observed that there is increasing resistance to antibiotics, of many P. aeruginosa strains, which is caused both by acquired and intrinsic mechanisms; this necessitates the development of new treatment avenues.

31The research of, who tested the extract of S. hymettia, indicated that kaempferol-containing compounds were effective against P. aeruginosa. The extract of Bryophyllum pinnatum (Lank.) Oken also had some antibacterial activity against P. aeruginosa.

32The extract prepared by exhibited good antibacterial activity against P. aeruginosa. The extract of Bupleurum chinense, which has been already mentioned, proved effective against this pathogen. The extract from Y. gigantea, which contains kaempferol-3-O-α-l-rhamnoside, was found to have an antimicrobial potential against this pathogen.

3.7. Antibacterial Activity against Salmonella Spp.

33Salmonella is a common pathology in both developed and developing countries and represents a major public concern; there are over 2600 recorded serotypes. Salmonellae are foodborne pathogens, found mostly in poultry, eggs, and dairy products. Recently, there has been an increase in the number of antibiotic-resistant strains; these are strains of increased virulence that are associated with increased mortality.

34The extract of Uapaca heudelotti was effective, as an antimicrobial, against S. typhi. Another effective antimicrobial against this pathogen is the extract of Bryophyllum pinnatum (Lank.) Oken. The extract from Yucca gigantea also had an effect against S. typhimurium.

3.8. Antibacterial Activity against Staphylococcus Spp.

35Staphylococcus aureus is a frequent human commensal and a common cause of various infections in humans. It can cause a wide variety of pathologies and associated symptoms, ranging from skin and soft tissue infections to infective endocarditis; different staphylococcal strains are characterized by different aggressiveness properties. The importance of S. aureus as a pathogen is further highlighted by the emergence of increasing antibiotic resistance. The particular strain of Staphylococcus aureus which is resistant to methicillin is commonly referred to as MRSA (methicillin-resistant Staphylococcus aureus); it is a significant problem for health systems worldwide, both from a medical and a healthcare cost standpoint. Its incidence rates present significant variations depending on the countries and healthcare unit location but are nevertheless quite significant. The situation is aggravated even more since different types of MRSA have been identified, namely the healthcare-associated MRSA (HA-MRSA), the community-associated MRSA (CA-MRSA), and the livestock-acquired MRSA (LA-MRSA). A rather more benign species is S. epidermidis, a commensal which is not a frequent cause of disease, but it is of increasing importance in nosocomial settings; in healthcare unit settings, its infection rates are approximately commensurate with those of S. aureus.

36The early research of indicated that kaempferol-3,7-O-α-l-dirhamnoside was particularly effective against S. aureus. The research of, on the extract of Scabiosa hymettia, which contained two kaempferol-based flavonoids, corroborated the antibacterial action of kaempferol and its derivatives, against S. aureus; it was also active against S. epidermidis. The extract of M. scaber, a plant used in traditional West African medicine, also proved effective against S. aureus. It must be noted that in this last case, when the compounds of the extract were tested separately, kaempferol-3-O-rutinoside exhibited a low antibacterial action suggesting that either the antibacterial effects were attributable to other compounds or that it has some sort of synergistic action with some of the other compounds found in the extract. A degree of antibacterial activity, against S. aureus, was exhibited by some of the extracts of Allium ursinum from Bulgaria. The extract of Bryophyllum pinnatum (Lank.) Oken also exhibited interesting antibacterial properties against S. aureus.

37The experiments of determined that both kaempferol 3-O-α-L-(2″,4″-di-E-p-coumaroyl)-rhamnoside (C2) and kaempferol 3-O-α L-(2″-Z-p-coumaroyl-4″-E-p-coumaroyl)-rhamnoside (C3), exerted a strong antibacterial activity against different MRSA strains in vitro. These compounds were extracted from Laurus nobilis, and were virtually ineffective against Streptococcus pneumoniae, Pseudomonas aeruginosa, and Serratia marcescens. These same compounds were later found to have a synergistic effect with fluoroquinolones; namely, they increased the minimum inhibitory concentrations of these antibiotics. The same does not apply to hydrophobic quinolones.

38Contemporary research, studying the anti-MRSA activities of the extract from Platanus occidentalis, determined that the numerous contained kaempferol compounds exhibited a satisfactory level of anti-MRSA activity. The research of, expounding upon the previous data, identified four isomers of kaempferol-3-O-α-L-(2”,3”-di-p-coumaroyl)-rhamnoside, from the same plant, which all exhibit anti-MRSA activity. It is possible that the main effect of such kaempferol-containing extracts is mostly attributable to the inhibition of the synthesis of the staphylococcal proteins, as determined by. The earlier research of also identified kaempferol-3-O-(2″,3″,4″-tri-O-galloyl)-α-l-rhamnopyranoside, along with other compounds, in the extract of Calliandra tergemina (L.) Benth. The anti-MRSA activity of the extract was verified experimentally.

39The already mentioned research of indicated that kaempferol, in the form of nanocrystals, was effective against multi-drug resistant (MDR) S. aureus. Two different propolis extracts, which contained kaempferol, also proved effective against S. aureus. The earlier research of also indicated the effectiveness of a kaempferol-containing extract, against S. aureus. Another extract, from the plant B. chinense also proved effective against S. aureus; the results from the extract of Uapaca heudelotti against S. aureus were also positive. The combination of kaempferol with Ag nanoparticles was also effective against this pathogen. A successful result was also obtained by, who studied the effects of the extract of Y. gigantea; this extract was effective against S. epidermidis too.

3.9. Antibacterial Activity against Enterococci

40In the last decades, enterococci have become a concern as nosocomial pathogens of note; they have the potential to cause serious infections. The most important pathogens of the genus are Enterococcus faecium and Enterococcus faecalis. In particular, vancomycin-resistant enterococci (VRE) present a serious challenge because not only can they resist many antibiotics but they are quick to accrue further resistance.

41Based on the research of, kaempferol-3,7-O-α-l-dirhamnoside was quite effective against Enterococcus faecalis. The extract of Laurus nobilis, of, was also effective against VRE. The team of isolated kaempferol, amongst other compounds, from the plant Combretum erythrophyllum and found that it was effective, as an antibacterial, against E. faecalis.

3.10. Antibacterial Activity against Proteus Spp.

42Perhaps the most important representative of the infectious species of the genus Proteus is P. mirabilis, which causes infections of the urinary tract, such as cystitis and pyelonephritis; many cases of asymptomatic bacteriuria have been also documented, predominantly in elderly patients and individuals having type 2 diabetes. Such infections are also associated with urinary stone formation and even become life-threatening. P. vulgaris has also been implicated in resistant healthcare unit-acquired infections. Proteus infections can lead to catheter obstruction in catheterized patients and the urinary stones created may act as a focal point for further bacterial infections; indeed, catheterization is perhaps the dominant risk factor in Proteus infections. The bacteria of this genus are associated with numerous determinants of antibiotic resistance and there is even a number of MDR Proteus strains; the prevalence of such strains was recently estimated to be quite high, at least in certain settings.

43The already-mentioned extract of was effective against P. vulgaris. Of all the microorganisms tested in this study, P. vulgaris proved to be the most susceptible. On the other hand, Proteus mirabilis proved quite resistant to kaempferol-3,7-O-α-l-dirhamnoside. However, the extract studied by was effective against this species, as well as the extract of Uapaca heudelotti. This bacterial species proved also susceptible to the extract of Y. gigantea, which contains kaempferol-3-O-α-l-rhamnoside.

3.11. Antibacterial Activity against Vibrio cholerae

44Cholera is most certainly an ancient disease of humans, although it has become a major health concern after the 19th century; it is a physiological inhabitant of aquatic ecosystems. There is a number of pathogenic biotypes and there are several virulence factors. The emergence of resistant strains of Vibrio cholerae has been documented in the past and further resistance mechanisms continue to be observed.

45Kaempferol and some of its derivatives were found to be effective against Vibrio cholerae, showing good antibacterial activity; in particular, kaempferol did not exhibit side effects such as toxicity to lymphocytes.

4. Antifungal Properties of Kaempferol

46A very small number of fungi species are pathogenic to humans; of these pathogenic fungi, some cause mild infections, while others, such as Candida spp. and Aspergillus spp., can even cause life-threatening, systemic infections. Based on recent research, infections by Candida species, in hospital settings, represent an increasing health problem. While fungi of this genus are generally benign, they can be the cause of oral candidiasis; in women, a significant percentage will suffer, sometime in their lives, from vaginal candidiasis. Infections by Candida species are mostly determined by risk factors.

47Likewise, Aspergillus fumigatus, while harmless to the immunocompetent host, will cause aspergillosis in immunocompromised patients; this represents an increasing concern with the number of such patients rising. It is important to note that it is virtually impossible to evade exposure to this pathogen, as humans ingest hundreds of its conidia on a daily basis. Another important aspect of A. fumigatus infections is that they may occur in the cavities left over in patients who have recovered from tuberculosis; this is interesting, considering that kaempferol is known to be effective against M. tuberculosis, as already discussed. Therefore, for this specific case, a kaempferol-containing agent could both suppress the initial infection and act preventatively against possible aspergillosis.

48Finally, Cryptococcus neoformans is one of the deadliest fungal pathogens and, according to a recent survey kills thousands of infected patients each year. Its importance as a disease of global interest was realized after the 1970s. Several risk factors are associated with an increased risk of cryptococcosis infection; for example, as happens with other pathogens, cryptococcosis is particularly dangerous for HIV/AIDS patients. In general, despite the availability of antifungal drugs, there is an emerging resistance as the microorganisms adapt; coupled with the known side effects of many antifungal drugs, the importance of the development of novel therapeutic strategies, based on natural compounds becomes all the more obvious.

49Probably the first antifungal action of a kaempferol-containing compound was documented by, who tested the extract of Mitracarpus scaber, a plant used in traditional West African medicine. Both isolated kaempferol-3-O-[3-O-acetyl-6-O-(E)-p-coumaroyl]-b-d-glucopyranoside and kaempferol 3-O-b-D-kaempferol 3-O-b-D-glucopyranoside, from S. hymettia, were found to be active in vitro against C. albicans, C. glabrata and C. tropicalis. As mentioned above, the kaempferol compound of the extract was not as effective when tested in isolated form. Moderate antifungal activity, against C. albicans was exhibited by some kaempferol-containing extracts from Allium ursinum. The extract from Labisa pumila Benth, discussed before, also has a quite notable antifungal effect. The extract from Bryophyllum pinnatum (Lank.) Oken exhibited interesting antifungal activity against C. albicans, C. parapsilosis and also Cryptococcus neoformans.

50A comparatively weak inhibitory activity, at maximum concentration, was exhibited by kaempferol-3-O-(6”-galloyl)-β-D-glucopyranoside, isolated from Baseonema acuminatum. Pure kaempferol also proved very effective against C. albicans both in vitro and in vivo in mice. A possible effect against fungi of the Candida spp. was reported for the extract of Trachyspermum ammi, which contained kaempferol-(coumaroyl glucosyl)-rhamnoside. The extract from Y. gigantea had a definite antifungal effect. In the recent research of, it was determined, based on binding mechanisms, that kaempferol, at least when contained in an extract, may have a significant fungicidal effect in cases of vaginal candidiasis.

51The antifungal activity of kaempferol was also proven by the research of. The extract prepared by, which also contained many other phytochemicals, had antifungal activity against Candida albicans and Aspergillus fumigatus. Moreover, significant fungistatic activity was exhibited by the bark extract of Spondias mombin. A summary of the research on the antifungal properties of kaempferol mentioned in the text is presented in Table 4.

5. Antiprotozoal Properties of Kaempferol

52Plant extracts containing kaempferol have shown antiprotozoal activity based on a number of researches against some of the most common protozoal pathogens (Table 5). In this section, we will review the most prominent research and list the plants identified as possible sources of cure and prevention (Table 6).

5.1. Antiprotozoal Action against Entamoeba histolytica and Giardia lamblia

53Probably the first description of an antiprotozoal activity of a kaempferol-containing extract was made by who studied the extract of Helianthemum glomeratum against Entamoeba histolytica in vitro, with successful results. Shortly after, kaempferol was also isolated from the roots of Cuphea pinetorum; it too was effective against E. histolytica and Giardia lamblia in vitro. The importance of kaempferol in the antiprotozoal activity of these extracts was verified by. The antiprotozoal activity of H. glomeratum, and the importance of kaempferol, were also examined by. These plants are used in Mayan traditional medicine. The same promising results against E. histolytica were obtained when using the extract of Morinda morindoides. The potency of kaempferol against E. histolytica was also demonstrated by. Against both E. histolytica and G. lamblia, kaempferol-3,7-dimethylether was shown to have a degree of antiprotozoal activity in vitro. This antiprotozoal activity of kaempferol against E. histolytica is important in the wider context of the activity of numerous flavonoids against this parasite; such natural compounds may enable the development of new drugs against resistant parasites.

5.2. Antiprotozoal Action against Trypanosoma Spp.

54This disease, also known as the sleeping sickness, is caused by Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense. It is a disease endemic to African countries. It is mainly transmitted by flies of the genus Glossina, although transmission by other blood-sucking insects has also been documented; it has even been proposed that due to the different possibilities of transmission, there may be outbreaks of this disease in non-endemic areas. The treatment of this disease is based on a few drugs, which can be divided into two groups, the blood–brain barrier-crossing drugs (melarsoprol, eflornithine, nifurtimox) and the non-blood–brain barrier-crossing drugs (pentamidine, suramin). While currently there is a decrease in human African trypanosomiasis cases. At the moment, resistance to treatment is not a massive issue for this particular disease, although resistant cases have been clinically reported; furthermore, effective treatment options are required for the final stages of the disease.

55Kaempferol-7-methylether was one of the compounds identified in the extract of Alomia myriadenia which was very effective against Trypanosoma cruzi in vitro. On the other hand, the kaempferol-containing extract of Conyza filaginoides, was not found to be effective against Trypanosoma spp. and Giardia spp.. Possibly, kaempferol is also important in the antiprotozoal activity exhibited by the bark extract of Cayratia trifolia Linn. Contrary to that, the results of were disappointing in that regard. Another research, focusing on kaempferol-3-O-methylether-5-O-β-D-glucoside and kaempferol-8-hydroxy-3,7-O-dimethylether-5-O-β-D-glucoside, from the extract of the plant Zanthoxylum pistaciifolium Griseb. found that they had no significant activity against either T. cruzi or T. brucei. The compound 4′-methoxykaempferol, isolated from the extract of temperate propolis, proved to be quite effective against T. brucei. The extract of Lotus corniculatus L. was found to be effective against Trypanosoma spp..

5.3. Antiprotozoal Action against Plasmidium Spp.

56Malaria is a well-known disease since ancient times and is caused by the amoeboid intracellular parasite Plasmodium; five of the 172 Plasmodium species are infectious to humans (P. malariae, P.falciparum, P.vivax, P.ovale, P.knowlesi); others are rarely infectious. Regardless, their morphology and biology are quite similar. The transmission of malaria is performed through its vectors, the female mosquitoes of the genus Anopheles; subsequently, the parasite will infect first the hepatocytes and then the erythrocytes. Currently, the most widespread therapy against malaria is the use of artemisinin and artemisinin-based combination therapy (ACT). In addition, there is an emerging resistance to antimalarial drugs, which threatens future efforts to eliminate the disease. While endemic malaria is a major health concern, it may even be a health hazard in non-endemic countries.

57Interestingly, 8-(1;1)-DMA-kaempferide, a flavonoid very similar to kaempferol, was found to have an antiprotozoal potential against Plasmidium falciparum. Based on the research of, the extract of Eupatorium perfoliatum L. exhibited an in vitro antiprotozoal activity against P. falciparum; the extract contained kaempferol but the dimeric guaianolide was shown to be the most important part of the antiprotozoal activity. Some kaempferol metabolites proved to be effective against the malaria parasite when isolated in vitro. The inability of kaempferol to influence negatively the formation of hemozoin, lead to suggest that the in vitro antiplasmodial activity of kaempferol must not be related to any heme-binding activity pathway. The aforementioned study of, found two kaempferol glycosides to be ineffective against P. falciparum. Finally, the extract of Lotus corniculatus L., which contains pure kaempferol alongside some other kaempferol compounds has antiprotozoal activity against Plasmodium spp..

5.4. Antiprotozoal Action against Leishmania Spp.

58Leishmaniasis is a tropical and subtropical disease, mainly transmitted to humans through the sand flies of the genuses Phlebotomus and Lutzomyia. The disease is extremely dangerous and presents a variety of symptoms; occasionally it can be fatal. There exist over 20 species of the Leishmania parasite which can infect humans; leishmaniasis is a zoonosis and can be divided into visceral, cutaneous, and mucocutaneous. The traditional treatment for leishmaniasis is based on antimonials, against which there is, however, increasing resistance; antimonials also have frequent and rather severe side effects.

59Compounds from the extract of K. pinatta were found to have antileishmanial activity. In an in vitro assay, kaempferol-3,7-di-O-methylether was found to be able to induce cell death in Leishmania amazonensis. When isolated from temperate propolis, 4′,7-dimethoxykaempferol was found to be quite effective against L. amazonensis in vitro.

6. Kaempferol-Containing Plants in Traditional Medical Systems

60As mentioned elsewhere in this paper, a number of plants that contain kaempferol compounds are included in many traditional medical systems, all around the world. It is interesting to note that their traditional applications frequently correspond with their current effects under research. In this section, we will group the most important such plants, and their applications mentioned in this paper (Table 7), and then briefly examine the importance of some kaempferol-containing plants in the context of traditional Chinese medicine.

Kaempferol-Containing Plants in the Context of Traditional Chinese Medicine

61Herbal medicine is still regarded as an integral part of Traditional Chinese Medicine, and continues to be relevant in all parts of the world. As has been already proven, the study of these ancient practices can lead to novel therapies and drug discovery.

62The use of the flower of the clove, known as dingxiang, is indicated to counteract the invasion of cold, and also to warm the kidneys; associated clinical signs include vomiting, hiccup, diarrhea, impotence, and leg weakness.

63Bupleurum chinense, also known as radix bupleuri, or chaixu, is used in a variety of herbal formulas, which are associated with harmonizing lesser yang-stage disorders; some formulas, are also used against malaria. Other formulas, containing B. chinense are used to release exterior wind and heat. To be more precise, radix bupleuri is derived from the roots of B. chinense. Modern phytochemical research indicates that it has a wide range of pharmacological effects.

64Geranium is also used in Traditional Chinese Medicine, both in anti-inflammatory and anti-microorganism applications; current research has verified its anti-inflammatory potential.

65Astragalus creticus is a plant that is endemic both to Greece and China; it is used, either alone or in herbal formulas to warm the meridians and dispel cold. In warming the meridians, it is ideal for rectifying the deficiency of the lung, spleen, and stomach meridians. In Western Medicine terminology, it is used in cases of body weakness, as a diuretic, against digestive system disorders, or simply as a food supplement. This is one of the most widespread plant genuses, and it has numerous ethnobotanical applications. It would be interesting to compare the similarities between the applications of these plants in different medical systems.

66Lastly, propolis, which is a bee product containing plant elements, not a plant per se, is an integral compound of many medicinal systems. It is used in traditional Chinese medicine, for its anti-inflammatory properties and also has an anti-diabetic potential.

7. Discussion and Conclusions

67In recent years, the field of phytochemistry has been rapidly developing with the aim of developing new drugs based on plant-derived compounds. At the same time, the field of ethnopharmacology studies the use of traditional medicinal plants of different regions and their possible applications in modern medical and pharmacological practice. Such approaches are integrated into the innovative practices which constitute the driving force behind the development of new therapeutical approaches.

68As discussed in this paper, plants that contain kaempferol and its associated compounds have been tested for a number of effects, from anticarcinogenic to antibacterial, antifungal, and antiprotozoal. Indeed, the identification of natural compounds with anticarcinogenic potential has been a mainstay of medical research in the last decades. Applications of such products have been proposed by and the related new perspectives in drug discovery of many such natural agents have been summarized by.

69Regarding the focus of this paper, in light of the promising effects of kaempferol compounds in the field of clinical microbiology, it can be said with a degree of certainty that it represents a novel potential for drug design. This is all the more important given the emerging resistance of many pathogens to traditional drugs. We may further postulate that given the wide range of kaempferol effects, drugs that may combat more than one condition may be developed; for example, using kaempferol as the basic agent, infections in cancer patients may be treated, combatting the pathogen and the cancer cells at the same time. This is a subject for future research.

70Finally, as presented in the last part of the paper, kaempferol-containing plants are found in the traditional medicinal systems of almost every region; this attests to the efficacy of such treatments. In the particular case of traditional Chinese medicine, more often than not, such plants are used in conjunction with other plants and herbs, in herbal formulas. We propose, from a future research perspective, that these formulas should be tested, initially in vitro, to ascertain the relative efficacy of their components, and whether the kaempferol compounds of the ingredients can exert their actions on their own or in tandem with some of the other contained compounds.

References 464

1.
Veeresham C. Natural products derived from plants as a source of drugs. J. Adv. Pharm. Technol. Res. 2012;3:200-201.
Not in our library10.4103/2231-4040.104709
2.
Katiyar C., Gupta A., Kanjilal S., Katiyar S. Drug discovery from plant sources: An integrated approach. Ayu. 2012;33:10-19.
Not in our library10.4103/0974-8520.100295
3.
Seidel V. Plant-Derived Chemicals: A Source of Inspiration for New Drugs. Plants. 2020;9:1562.
Not in our library10.3390/plants9111562
4.
Petran M., Dragos D., Gilca M. Historical ethnobotanical review of medicinal plants used to treat children diseases in Romania (1860s–1970s). J. Ethnobiol. Ethnomedicine. 2020;16:15.
Not in our library10.1186/s13002-020-00364-6
5.
Verma A.R., Vijayakumar M., Mathela C.S., Rao C.V. In vitro and in vivo antioxidant properties of different fractions of Moringa oleifera leaves. Food Chem. Toxicol. 2009;47:2196-2201.
Not in our library10.1016/j.fct.2009.06.005
6.
Gilca M., Gaman L., Panait E., Stoian I., Atanasiu V. Chelidonium majus–an integrative review: Traditional knowledge versus modern findings. Complement. Med. Res. 2010;17:241-248.
Not in our library10.1159/000321397
7.
Singh N., Bhalla M., de Jager P., Gilca M. An overview on ashwagandha: A Rasayana (rejuvenator) of Ayurveda. Afr. J. Tradit. Complement. Altern. Med. 2011;8:208-213.
Not in our library10.4314/ajtcam.v8i5s.9
8.
Singh N., Pandey B., Verma P., Bhalla M., Gilca M. Phyto-pharmacotherapeutics of Cyperus rotundus Linn.(Motha): An overview. Indian J. Nat. Prod. Res. 2012;3:467-476.
Not in our library
9.
Liu R.H. Health-promoting components of fruits and vegetables in the diet. Adv. Nutr. 2013;4:384s-392s.
Not in our library10.3945/an.112.003517
10.
Reedy J., Krebs-Smith S.M., Miller P.E., Liese A.D., Kahle L.L., Park Y., Subar A.F. Higher Diet Quality Is Associated with Decreased Risk of All-Cause, Cardiovascular Disease, and Cancer Mortality among Older Adults. J. Nutr. 2014;144:881-889.
Not in our library10.3945/jn.113.189407
11.
Bontempo P., De Masi L., Carafa V., Rigano D., Scisciola L., Iside C., Grassi R., Molinari A.M., Aversano R., Nebbioso A., et al. Anticancer activities of anthocyanin extract from genotyped Solanum tuberosum L. “Vitelotte”. J. Funct. Foods. 2015;19:584-593.
Not in our library10.1016/j.jff.2015.09.063
12.
Siri-Tarino P.W., Krauss R.M. Diet, lipids, and cardiovascular disease. Curr. Opin. Lipidol. 2016;27:323-328.
Not in our library10.1097/mol.0000000000000310
13.
Lange K.W., Lange K.M., Makulska-Gertruda E., Nakamura Y., Reissmann A., Kanaya S., Hauser J. Ketogenic diets and Alzheimer’s disease. Food Sci. Hum. Wellness. 2017;6:1-9.
Not in our library10.1016/j.fshw.2016.10.003
14.
Playdon M.C., Nagle C.M., Ibiebele T.I., Ferrucci L.M., Protani M.M., Carter J., Hyde S.E., Neesham D., Nicklin J.L., Mayne S.T., et al. Pre-diagnosis diet and survival after a diagnosis of ovarian cancer. Br. J. Cancer. 2017;116:1627-1637.
Not in our library10.1038/bjc.2017.120
15.
Periferakis A., Periferakis K. On the Dissemination of Acupuncture to Europe. JournalNX. 2020;6:201-209.
Not in our library
16.
Farombi E.O., Akinmoladun A.C., Owumi S.E., Melton L., Shahidi F., Varelis P. Anti-Cancer Foods: Flavonoids. Encyclopedia of Food Chemistry. 2019;224-236.
Not in our library10.1016/b978-0-08-100596-5.21757-5
17.
Havsteen B.H. The biochemistry and medical significance of the flavonoids. Pharmacol. Ther. 2002;96:67-202.
Not in our library10.1016/s0163-7258(02)00298-x
18.
Flavonoids: an overview · 2016
No notice
19.
Corradini E., Foglia P., Giansanti P., Gubbiotti R., Samperi R., Laganà A. Flavonoids: Chemical properties and analytical methodologies of identification and quantitation in foods and plants. Nat. Prod. Res. 2011;25:469-495.
Not in our library10.1080/14786419.2010.482054
20.
Cancer chemoprevention through dietary flavonoids: what’s limiting? · 2017
Corrected
21.
George V.C., Dellaire G., Rupasinghe H.P.V. Plant flavonoids in cancer chemoprevention: Role in genome stability. J. Nutr. Biochem. 2017;45:1-14.
Not in our library10.1016/j.jnutbio.2016.11.007
22.
Farombi E.O., Shrotriya S., Surh Y.-J. Kolaviron inhibits dimethyl nitrosamine-induced liver injury by suppressing COX-2 and iNOS expression via NF-κB and AP-1. Life Sci. 2009;84:149-155.
Not in our library10.1016/j.lfs.2008.11.012
23.
Olaleye M.T., Amobonye A.E., Komolafe K., Akinmoladun A.C. Protective effects of Parinari curatellifolia flavonoids against acetaminophen-induced hepatic necrosis in rats. Saudi J. Biol. Sci. 2014;21:486-492.
Not in our library10.1016/j.sjbs.2014.06.005
24.
Vázquez-Flores L.F., Casas-Grajales S., Hernández-Aquino E., Vargas-Pozada E.E., Muriel P., Muriel P. Chapter 47—Antioxidant, Antiinflammatory, and Antifibrotic Properties of Quercetin in the Liver. Liver Pathophysiology. 2017;653-674.
Not in our library10.1016/b978-0-12-804274-8.00047-3
25.
Bahrin L.G., Apostu M.O., Birsa L.M., Stefan M. The antibacterial properties of sulfur containing flavonoids. Bioorganic Med. Chem. Lett. 2014;24:2315-2318.
Not in our library10.1016/j.bmcl.2014.03.071
26.
Iranshahi M., Rezaee R., Parhiz H., Roohbakhsh A., Soltani F. Protective effects of flavonoids against microbes and toxins: The cases of hesperidin and hesperetin. Life Sci. 2015;137:125-132.
Not in our library10.1016/j.lfs.2015.07.014
27.
Athira K.V., Madhana R.M., Lahkar M. Flavonoids, the emerging dietary supplement against cisplatin-induced nephrotoxicity. Chem. -Biol. Interact. 2016;248:18-20.
Not in our library10.1016/j.cbi.2016.02.005
28.
Cai H.-D., Su S.-L., Qian D.-W., Guo S., Tao W.-W., Cong X.D., Tang R., Duan J.-A. Renal protective effect and action mechanism of Huangkui capsule and its main five flavonoids. J. Ethnopharmacol. 2017;206:152-159.
Not in our library10.1016/j.jep.2017.02.046
29.
Unnikrishnan M.K., Veerapur V., Nayak Y., Mudgal P.P., Mathew G., Watson R.R., Preedy V.R., Zibadi S. Chapter 13—Antidiabetic, Antihyperlipidemic and Antioxidant Effects of the Flavonoids. Polyphenols in Human Health and Disease. 2014;143-161.
Not in our library10.1016/b978-0-12-398456-2.00013-x
30.
Keshari A.K., Kumar G., Kushwaha P.S., Bhardwaj M., Kumar P., Rawat A., Kumar D., Prakash A., Ghosh B., Saha S. Isolated flavonoids from Ficus racemosa stem bark possess antidiabetic, hypolipidemic and protective effects in albino Wistar rats. J. Ethnopharmacol. 2016;181:252-262.
Not in our library10.1016/j.jep.2016.02.004
31.
Olaleye M.T., Crown O.O., Akinmoladun A.C., Akindahunsi A.A. Rutin and quercetin show greater efficacy than nifedipin in ameliorating hemodynamic, redox, and metabolite imbalances in sodium chloride-induced hypertensive rats. Hum. Exp. Toxicol. 2014;33:602-608.
Not in our library10.1177/0960327113504790
32.
Testai L. Flavonoids and mitochondrial pharmacology: A new paradigm for cardioprotection. Life Sci. 2015;135:68-76.
Not in our library10.1016/j.lfs.2015.04.017
33.
Somasundaram S.G., Oommen B., Watson R.R., Preedy V.R. Chapter 1—Antioxidant Flavonoids for Arthritis Treatment: Human and Animal Models. Bioactive Food as Dietary Interventions for Arthritis and Related Inflammatory Diseases. 2013;1-16.
Not in our library10.1016/b978-0-12-397156-2.00001-6
34.
Choudhary N., Bijjem K.R.V., Kalia A.N. Antiepileptic potential of flavonoids fraction from the leaves of Anisomeles malabarica. J. Ethnopharmacol. 2011;135:238-242.
Not in our library10.1016/j.jep.2011.02.019
35.
Nabavi S.F., Braidy N., Habtemariam S., Orhan I.E., Daglia M., Manayi A., Gortzi O., Nabavi S.M. Neuroprotective effects of chrysin: From chemistry to medicine. Neurochem. Int. 2015;90:224-231.
Not in our library10.1016/j.neuint.2015.09.006
36.
Falode J.A., Akinmoladun A.C., Olaleye M.T., Akindahunsi A.A. Sausage tree (Kigelia africana) flavonoid extract is neuroprotective in AlCl(3)-induced experimental Alzheimer’s disease. Pathophysiology. 2017;24:251-259.
Not in our library10.1016/j.pathophys.2017.06.001
37.
Preethi Pallavi M.C., Sampath Kumar H.M., Brahmachari G. Chapter 8—Nutraceuticals in Prophylaxis and Therapy of Neurodegenerative Diseases. Discovery and Development of Neuroprotective Agents from Natural Products. 2018;359-376.
Not in our library10.1016/b978-0-12-809593-5.00008-2
38.
Flavonoids with Gastroprotective Activity · 2009
No notice
39.
Antonisamy P., Subash-Babu P., Albert-Baskar A., Alshatwi A.A., Aravinthan A., Ignacimuthu S., Choi K.C., Lee S.C., Kim J.-H. Experimental study on gastroprotective efficacy and mechanisms of luteolin-7-O-glucoside isolated from Ophiorrhiza mungos Linn. in different experimental models. J. Funct. Foods. 2016;25:302-313.
Not in our library10.1016/j.jff.2016.06.003
40.
Nwankwo J.O., Tahnteng J.G., Emerole G.O. Inhibition of aflatoxin B1 genotoxicity in human liver-derived HepG2 cells by kolaviron biflavonoids and molecular mechanisms of action. Eur. J. Cancer Prev. 2000;9:351-361.
Not in our library10.1097/00008469-200010000-00010
41.
Snijman P.W., Swanevelder S., Joubert E., Green I.R., Gelderblom W.C.A. The antimutagenic activity of the major flavonoids of rooibos (Aspalathus linearis): Some dose–response effects on mutagen activation–flavonoid interactions. Mutat. Res. Genet. Toxicol. Environ. Mutagen. 2007;631:111-123.
Not in our library10.1016/j.mrgentox.2007.03.009
42.
Carvalho-Silva L.B.D., Dionísio A.P., Pereira A.C.D.S., Wurlitzer N.J., Brito E.S.D., Bataglion G.A., Brasil I.M., Eberlin M.N., Liu R.H. Antiproliferative, antimutagenic and antioxidant activities of a Brazilian tropical fruit juice. LWT—Food Sci. Technol. 2014;59:1319-1324.
Not in our library10.1016/j.lwt.2014.04.002
43.
Serpeloni J.M., Leal Specian A.F., Ribeiro D.L., Tuttis K., Vilegas W., Martínez-López W., Dokkedal A.L., Saldanha L.L., de Syllos Cólus I.M., Varanda E.A. Antimutagenicity and induction of antioxidant defense by flavonoid rich extract of Myrcia bella Cambess. in normal and tumor gastric cells. J. Ethnopharmacol. 2015;176:345-355.
Not in our library10.1016/j.jep.2015.11.003
44.
Zarev Y., Foubert K., Lucia de Almeida V., Anthonissen R., Elgorashi E., Apers S., Ionkova I., Verschaeve L., Pieters L. Antigenotoxic prenylated flavonoids from stem bark of Erythrina latissima. Phytochemistry. 2017;141:140-146.
Not in our library10.1016/j.phytochem.2017.06.003
45.
Neuhouser M.L. Dietary flavonoids and cancer risk: Evidence from human population studies. Nutr. Cancer. 2004;50:1-7.
Not in our library10.1207/s15327914nc5001_1
46.
Pei J., Chen A., Zhao L., Cao F., Ding G., Xiao W. One-Pot Synthesis of Hyperoside by a Three-Enzyme Cascade Using a UDP-Galactose Regeneration System. J. Agric. Food Chem. 2017;65:6042-6048.
Not in our library10.1021/acs.jafc.7b02320
47.
Weng C.J., Yen G.C. Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities. Cancer Metastasis Rev. 2012;31:323-351.
Not in our library10.1007/s10555-012-9347-y
48.
Zamora-Ros R., Sacerdote C., Ricceri F., Weiderpass E., Roswall N., Buckland G., St-Jules D.E., Overvad K., Kyrø C., Fagherazzi G., et al. Flavonoid and lignan intake in relation to bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Br. J. Cancer. 2014;111:1870-1880.
Not in our library10.1038/bjc.2014.459
49.
Petrick J.L., Steck S.E., Bradshaw P.T., Trivers K.F., Abrahamson P.E., Engel L.S., He K., Chow W.H., Mayne S.T., Risch H.A., et al. Dietary intake of flavonoids and oesophageal and gastric cancer: Incidence and survival in the United States of America (USA). Br. J. Cancer. 2015;112:1291-1300.
Not in our library10.1038/bjc.2015.25
50.
Kaempferol as a Dietary Anti-Inflammatory Agent: Current Therapeutic Standing · 2020
No notice
51.
Park U.H., Hwang J.T., Youn H., Kim E.J., Um S.J. Kaempferol antagonizes adipogenesis by repressing histone H3K4 methylation at PPARγ target genes. Biochem. Biophys. Res. Commun. 2022;617:48-54.
Not in our library10.1016/j.bbrc.2022.05.098
52.
Beltz L.A., Bayer D.K., Moss A.L., Simet I.M. Mechanisms of cancer prevention by green and black tea polyphenols. Anticancer Agents Med. Chem. 2006;6:389-406.
Not in our library10.2174/187152006778226468
53.
Chemistry and Biological Activities of Flavonoids: An Overview · 2013
No notice
54.
Calderón-Montaño J.M., Burgos-Morón E., Pérez-Guerrero C., López-Lázaro M. A review on the dietary flavonoid kaempferol. Mini Rev. Med. Chem. 2011;11:298-344.
Not in our library10.2174/138955711795305335
55.
Santos-Buelga C., Feliciano A.S. Flavonoids: From Structure to Health Issues. Molecules. 2017;22:477.
Not in our library10.3390/molecules22030477
56.
Mousdale D.M., Coggins J.R. Subcellular localization of the common shikimate-pathway enzymes in Pisum sativum L. Planta. 1985;163:241-249.
Not in our library10.1007/bf00393514
57.
Jung E., Zamir L.O., Jensen R.A. Chloroplasts of higher plants synthesize L-phenylalanine via L-arogenate. Proc. Natl. Acad. Sci. USA. 1986;83:7231-7235.
Not in our library10.1073/pnas.83.19.7231
58.
Benesova M., Bode R. Chorismate mutase isoforms from seeds and seedlings of Papaver somniferum. Phytochemistry. 1992;31:2983-2987.
Not in our library10.1016/0031-9422(92)83431-w
59.
Xiao J. Dietary flavonoid aglycones and their glycosides: Which show better biological significance? Crit. Rev. Food Sci. Nutr. 2017;57:1874-1905.
Not in our library10.1080/10408398.2015.1032400
60.
Santos M., Fortunato R.H., Spotorno V.G. Analysis of flavonoid glycosides with potential medicinal properties on Bauhinia uruguayensis and Bauhinia forficata subspecies pruinosa. Nat. Prod. Res. 2019;33:2574-2578.
Not in our library10.1080/14786419.2018.1460826
61.
Rha C.S., Jeong H.W., Park S., Lee S., Jung Y.S., Kim D.O. Antioxidative, Anti-Inflammatory, and Anticancer Effects of Purified Flavonol Glycosides and Aglycones in Green Tea. Antioxidants. 2019;8:278.
Not in our library10.3390/antiox8080278
62.
Viskupicova J., Ondrejovič M., Sturdik E. Bioavailability and metabolism of flavonoids. J. Food Nutr. Res. 2008;47:151-162.
Not in our library
63.
Bangar S.P., Chaudhary V., Sharma N., Bansal V., Ozogul F., Lorenzo J.M. Kaempferol: A flavonoid with wider biological activities and its applications. Crit. Rev. Food Sci. Nutr. 2022;1-25.
Not in our library10.1080/10408398.2022.2067121
64.
Williamson G., Kay C.D., Crozier A. The Bioavailability, Transport, and Bioactivity of Dietary Flavonoids: A Review from a Historical Perspective. Compr. Rev. Food Sci. Food Saf. 2018;17:1054-1112.
Not in our library10.1111/1541-4337.12351
65.
Németh K., Plumb G.W., Berrin J.G., Juge N., Jacob R., Naim H.Y., Williamson G., Swallow D.M., Kroon P.A. Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans. Eur. J. Nutr. 2003;42:29-42.
Not in our library10.1007/s00394-003-0397-3
66.
Nielsen S.E., Kall M., Justesen U., Schou A., Dragsted L.O. Human absorption and excretion of flavonoids after broccoli consumption. Cancer Lett. 1997;114:173-174.
Not in our library10.1016/s0304-3835(97)04654-5
67.
Terao J. Dietary flavonoids as antioxidants. Forum. Nutr. 2009;61:87-94.
Not in our library10.1159/000212741
68.
Chen A.Y., Chen Y.C. A review of the dietary flavonoid, kaempferol on human health and cancer chemoprevention. Food Chem. 2013;138:2099-2107.
Not in our library10.1016/j.foodchem.2012.11.139
69.
de Vries J.H., Hollman P.C., Meyboom S., Buysman M.N., Zock P.L., van Staveren W.A., Katan M.B. Plasma concentrations and urinary excretion of the antioxidant flavonols quercetin and kaempferol as biomarkers for dietary intake. Am. J. Clin. Nutr. 1998;68:60-65.
Not in our library10.1093/ajcn/68.1.60
70.
The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids · 2017
No notice
71.
Dietary Quercetin and Kaempferol: Bioavailability and Potential Cardiovascular-Related Bioactivity in Humans · 2019
No notice
72.
Cavalier-Smith T. A revised six-kingdom system of life. Biol. Rev. Camb. Philos. Soc. 1998;73:203-266.
Not in our library10.1017/s0006323198005167
73.
Markham K.R., Geiger H., Jaggy H. Kaempferol-3-O-glucosyl(1-2)rhamnoside from Ginkgo biloba and a reappraisal of other gluco(1-2, 1-3 and 1-4)rhamnoside structures. Phytochemistry. 1992;31:1009-1011.
Not in our library10.1016/0031-9422(92)80058-m
74.
Tang Y., Lou F., Wang J., Li Y., Zhuang S. Coumaroyl flavonol glycosides from the leaves of Ginkgo biloba. Phytochemistry. 2001;58:1251-1256.
Not in our library10.1016/s0031-9422(01)00320-x
75.
Zheng W., Wang S.Y. Antioxidant Activity and Phenolic Compounds in Selected Herbs. J. Agric. Food Chem. 2001;49:5165-5170.
Not in our library10.1021/jf010697n
76.
Lee H.S., Kim M.J. Selective responses of three Ginkgo biloba leaf-derived constituents on human intestinal bacteria. J. Agric. Food Chem. 2002;50:1840-1844.
Not in our library10.1021/jf011140a
77.
Krauze-Baranowska M. Flavonoids from the genus Taxus. Z. Naturforsch C J. Biosci. 2004;59:43-47.
Not in our library10.1515/znc-2004-1-210
78.
von Moltke L.L., Weemhoff J.L., Bedir E., Khan I.A., Harmatz J.S., Goldman P., Greenblatt D.J. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J. Pharm. Pharmacol. 2004;56:1039-1044.
Not in our library10.1211/0022357044021
79.
Yoon K.D., Jeong D.G., Hwang Y.H., Ryu J.M., Kim J. Inhibitors of Osteoclast Differentiation from Cephalotaxus koreana. J. Nat. Prod. 2007;70:2029-2032.
Not in our library10.1021/np070327e
80.
Kwon S.H., Nam J.I., Kim S.H., Kim J.H., Yoon J.H., Kim K.S. Kaempferol and quercetin, essential ingredients in Ginkgo biloba extract, inhibit interleukin-1beta-induced MUC5AC gene expression in human airway epithelial cells. Phytother. Res. 2009;23:1708-1712.
Not in our library10.1002/ptr.2817
81.
Group T.A.P., Chase M.W., Christenhusz M.J.M., Fay M.F., Byng J.W., Judd W.S., Soltis D.E., Mabberley D.J., Sennikov A.N., Soltis P.S., et al. An update of the Angiosperm Phylogeny Group classification for the orders and families of flowering plants: APG IV. Bot. J. Linn. Soc. 2016;181:1-20.
Not in our library10.1111/boj.12385
82.
I P. A community-derived classification for extant lycophytes and ferns. J. Syst. Evol. 2016;54:563-603.
Not in our library10.1111/jse.12229
83.
Christenhusz M., Reveal J., Farjon A., Gardner M., Mill R., Chase M. A new classification and linear sequence of extant gymnosperms. Nov. Magnolia Press Phytotaxa. 2010;19:55-70.
Not in our library10.11646/phytotaxa.19.1.3
84.
Arot Manguro L.O., Ugi I., Hermann R., Lemmen P. Flavonol and drimane-type sesquiterpene glycosides of Warburgia stuhlmannii leaves. Phytochemistry. 2003;63:497-502.
Not in our library10.1016/s0031-9422(03)00105-5
85.
Calzada F., Correa-Basurto J., Barbosa E., Mendez-Luna D., Yepez-Mulia L. Antiprotozoal Constituents from Annona cherimola Miller, a Plant Used in Mexican Traditional Medicine for the Treatment of Diarrhea and Dysentery. Pharmacogn. Mag. 2017;13:148-152.
Not in our library10.4103/0973-1296.197636
86.
Rodríguez Galdón B., Rodríguez Rodríguez E.M., Díaz Romero C. Flavonoids in onion cultivars (Allium cepa L.). J. Food Sci. 2008;73:C599-C605.
Not in our library10.1111/j.1750-3841.2008.00903.x
87.
Keyhanian S., Stahl-Biskup E. Phenolic constituents in dried flowers of aloe vera (Aloe barbadensis) and their in vitro antioxidative capacity. Planta Med. 2007;73:599-602.
Not in our library10.1055/s-2007-967202
88.
Vachálková A., Eisenreichová E., Haladová M., Mucaji P., Józová B., Novotný L. Potential carcinogenic and inhibitory activity of compounds isolated from Lilium candidum L. Neoplasma. 2000;47:313-318.
Not in our library
89.
Francis J.A., Rumbeiha W., Nair M.G. Constituents in Easter lily flowers with medicinal activity. Life Sci. 2004;76:671-683.
Not in our library10.1016/j.lfs.2004.10.001
90.
Xu J., Li X., Zhang P., Li Z.L., Wang Y. Antiinflammatory constituents from the roots of Smilax bockii warb. Arch. Pharmacal Res. 2005;28:395-399.
Not in our library10.1007/bf02977667
91.
Jiang R.-W., Zhou J.-R., Hon P.-M., Li S.-L., Zhou Y., Li L.-L., Ye W.-C., Xu H.-X., Shaw P.-C., But P.P.-H. Lignans from Dysosma versipellis with Inhibitory Effects on Prostate Cancer Cell Lines. J. Nat. Prod. 2007;70:283-286.
Not in our library10.1021/np060430o
92.
Marín C., Boutaleb-Charki S., Díaz J.G., Huertas O., Rosales M.J., Pérez-Cordon G., Guitierrez-Sánchez R., Sánchez-Moreno M. Antileishmaniasis activity of flavonoids from Consolida oliveriana. J. Nat. Prod. 2009;72:1069-1074.
Not in our library10.1021/np8008122
93.
Je Ma C., Jung W.J., Lee K.Y., Kim Y.C., Sung S.H. Calpain inhibitory flavonoids isolated from Orostachys japonicus. J. Enzym. Inhib. Med. Chem. 2009;24:676-679.
Not in our library10.1080/14756360802328075
94.
Jeong H.J., Ryu Y.B., Park S.J., Kim J.H., Kwon H.J., Kim J.H., Park K.H., Rho M.C., Lee W.S. Neuraminidase inhibitory activities of flavonols isolated from Rhodiola rosea roots and their in vitro anti-influenza viral activities. Bioorganic Med. Chem. 2009;17:6816-6823.
Not in our library10.1016/j.bmc.2009.08.036
95.
Song E.K., Kim J.H., Kim J.S., Cho H., Nan J.X., Sohn D.H., Ko G.I., Oh H., Kim Y.C. Hepatoprotective phenolic constituents of Rhodiola sachalinensis on tacrine-induced cytotoxicity in Hep G2 cells. Phytother. Res. 2003;17:563-565.
Not in our library10.1002/ptr.1166
96.
Antibacterial Activity of Kalanchoe mortagei and K. fedtschenkoi Against ESKAPE Pathogens · 2019
Not checked
97.
Saleem M., Kim H.J., Jin C., Lee Y.S. Antioxidant caffeic acid derivatives from leaves of Parthenocissus tricuspidata. Arch. Pharmacal Res. 2004;27:300-304.
Not in our library10.1007/bf02980064
98.
Kumar D., Kumar S., Gupta J., Arya R., Gupta A. A review on chemical and biological properties of Cayratia trifolia Linn. (Vitaceae). Pharmacogn. Rev. 2011;5:184-188.
Not in our library10.4103/0973-7847.91117
99.
Yin F., Zhang Y., Yang Z., Cheng Q., Hu L. Triterpene saponins from Gynostemma cardiospermum. J. Nat. Prod. 2006;69:1394-1398.
Not in our library10.1021/np0600898
100.
Ghaffari M.A., Chaudhry B.A., Uzair M., Imran M., Haneef M., Ashfaq K. Biological and phytochemical investigations of crude extracts of Astragalus creticus. Pak. J. Pharm. Sci. 2021;34:403-409.
Not in our library
101.
Mazimba O., Majinda R.R., Modibedi C., Masesane I.B., Cencič A., Chingwaru W. Tylosema esculentum extractives and their bioactivity. Bioorganic Med. Chem. 2011;19:5225-5230.
Not in our library10.1016/j.bmc.2011.07.006
102.
Nguyen T.T., Ketha A., Hieu H.V., Tatipamula V.B. In vitro antimycobacterial studies of flavonols from Bauhinia vahlii Wight and Arn. 3 Biotech. 2021;11:128.
Not in our library10.1007/s13205-021-02672-4
103.
Singh R., Singh B., Singh S., Kumar N., Kumar S., Arora S. Anti-free radical activities of kaempferol isolated from Acacia nilotica (L.) Willd. Ex. Del. Toxicol. Vitr. 2008;22:1965-1970.
Not in our library10.1016/j.tiv.2008.08.007
104.
Costa-Lotufo L.V., Jimenez P.C., Wilke D.V., Leal L.K., Cunha G.M., Silveira E.R., Canuto K.M., Viana G.S., Moraes M.E., de Moraes M.O., et al. Antiproliferative effects of several compounds isolated from Amburana cearensis A. C. Smith. Z. Naturforsch C J. Biosci. 2003;58:675-680.
Not in our library10.1515/znc-2003-9-1014
105.
Terreaux C., Wang Q., Ioset J.R., Ndjoko K., Grimminger W., Hostettmann K. Complete LC/MS analysis of a Tinnevelli senna pod extract and subsequent isolation and identification of two new benzophenone glucosides. Planta Med. 2002;68:349-354.
Not in our library10.1055/s-2002-26738
106.
Nsonde Ntandou G.F., Banzouzi J.T., Mbatchi B., Elion-Itou R.D., Etou-Ossibi A.W., Ramos S., Benoit-Vical F., Abena A.A., Ouamba J.M. Analgesic and anti-inflammatory effects of Cassia siamea Lam. stem bark extracts. J. Ethnopharmacol. 2010;127:108-111.
Not in our library10.1016/j.jep.2009.09.040
107.
Calvo T.R., Cardoso C.R.P., da Silva Moura A.C., dos Santos L.C., Colus I.M.S., Vilegas W., Varanda E.A. Mutagenic Activity of Indigofera truxillensis and I. suffruticosa Aerial Parts. Evid. -Based Complement. Altern. Med. 2011;2011:323276.
Not in our library10.1093/ecam/nep123
108.
Jiang H., Zhan W.Q., Liu X., Jiang S.X. Antioxidant activities of extracts and flavonoid compounds from Oxytropis falcate Bunge. Nat. Prod. Res. 2008;22:1650-1656.
Not in our library10.1080/14786410701875686
109.
Ali A.A., Mohamed M.H., Kamel M.S., Fouad M.A., Spring O. Studies on Securigera securidacea (L.) Deg. et Dörfl. (Fabaceae) seeds, an antidiabetic Egyptian folk medicine. Pharmazie. 1998;53:710-715.
Not in our library
110.
Xiang W., Li R.T., Mao Y.L., Zhang H.J., Li S.H., Song Q.S., Sun H.D. Four new prenylated isoflavonoids in Tadehagi triquetrum. J. Agric. Food Chem. 2005;53:267-271.
Not in our library10.1021/jf0483117
111.
Sharaf M. Chemical constituents from the seeds of Trifolium alexandrinum. Nat. Prod. Res. 2008;22:1620-1623.
Not in our library10.1080/14786410701869226
112.
Sharma U.K., Sharma K., Sharma N., Sharma A., Singh H.P., Sinha A.K. Microwave-assisted efficient extraction of different parts of Hippophae rhamnoides for the comparative evaluation of antioxidant activity and quantification of its phenolic constituents by reverse-phase high-performance liquid chromatography (RP-HPLC). J. Agric. Food Chem. 2008;56:374-379.
Not in our library10.1021/jf072510j
113.
Wei B.L., Lu C.M., Tsao L.T., Wang J.P., Lin C.N. In vitro anti-inflammatory effects of quercetin 3-O-methyl ether and other constituents from Rhamnus species. Planta Med. 2001;67:745-747.
Not in our library10.1055/s-2001-18339
114.
Goel R.K., Pandey V.B., Dwivedi S.P., Rao Y.V. Antiinflammatory and antiulcer effects of kaempferol, a flavone, isolated from Rhamnus procumbens. Indian J. Exp. Biol. 1988;26:121-124.
Not in our library
115.
Jung H.A., Jung M.J., Kim J.Y., Chung H.Y., Choi J.S. Inhibitory activity of flavonoids from Prunus davidiana and other flavonoids on total ROS and hydroxyl radical generation. Arch. Pharmacal Res. 2003;26:809-815.
Not in our library10.1007/bf02980025
116.
Nowak R., Gawlik-Dziki U. Polyphenols of Rosa L. leaves extracts and their radical scavenging activity. Z. Naturforsch C J. Biosci. 2007;62:32-38.
Not in our library10.1515/znc-2007-1-206
117.
Mahmood N., Piacente S., Pizza C., Burke A., Khan A.I., Hay A.J. The anti-HIV activity and mechanisms of action of pure compounds isolated from Rosa damascena. Biochem. Biophys. Res. Commun. 1996;229:73-79.
Not in our library10.1006/bbrc.1996.1759
118.
Suntornsuk L., Anurukvorakun O. Precision improvement for the analysis of flavonoids in selected Thai plants by capillary zone electrophoresis. Electrophoresis. 2005;26:648-660.
Not in our library10.1002/elps.200410203
119.
Niklas K.J., Giannasi D.E. Flavonoids and other chemical constituents of fossil miocene zelkova (ulmaceae). Science. 1977;196:877-878.
Not in our library10.1126/science.196.4292.877
120.
Fang X.K., Gao J., Zhu D.N. Kaempferol and quercetin isolated from Euonymus alatus improve glucose uptake of 3T3-L1 cells without adipogenesis activity. Life Sci. 2008;82:615-622.
Not in our library10.1016/j.lfs.2007.12.021
121.
Rocha L., Marston A., Potterat O., Kaplan M.A.C., Stoeckli-Evans H., Hostettmann K. Antibacterial phloroglucinols and flavonoids from Hypericum brasiliense. Phytochemistry. 1995;40:1447-1452.
Not in our library10.1016/0031-9422(95)00507-4
122.
Odabas M.S., Camas N., Cirak C., Radusiene J., Janulis V., Ivanauskas L. The quantitative effects of temperature and light intensity on phenolics accumulation in St. John’s wort (Hypericum perforatum). Nat. Prod. Commun. 2010;5:535-540.
Not in our library10.1177/1934578x1000500408
123.
Nguemeving J.R., Azebaze A.G.B., Kuete V., Eric Carly N.N., Beng V.P., Meyer M., Blond A., Bodo B., Nkengfack A.E. Laurentixanthones A and B, antimicrobial xanthones from Vismia laurentii. Phytochemistry. 2006;67:1341-1346.
Not in our library10.1016/j.phytochem.2006.03.018
124.
Pattamadilok D., Suttisri R. Seco-Terpenoids and Other Constituents from Elateriospermum tapos. J. Nat. Prod. 2008;71:292-294.
Not in our library10.1021/np070629g
125.
Oksüz S., Gürek F., Lin L.Z., Gil R.R., Pezzuto J.M., Cordell G.A. Aleppicatines A and B from Euphorbia aleppica. Phytochemistry. 1996;42:473-478.
Not in our library10.1016/0031-9422(95)00889-6
126.
Sousa M., Ousingsawat J., Seitz R., Puntheeranurak S., Regalado A., Schmidt A., Grego T., Jansakul C., Amaral M.D., Schreiber R., et al. An extract from the medicinal plant Phyllanthus acidus and its isolated compounds induce airway chloride secretion: A potential treatment for cystic fibrosis. Mol. Pharmacol. 2007;71:366-376.
Not in our library10.1124/mol.106.025262
127.
Yang R.Y., Lin S., Kuo G. Content and distribution of flavonoids among 91 edible plant species. Asia Pac. J. Clin. Nutr. 2008;17((Suppl. 1)):275-279.
Not in our library
128.
Penna C., Marino S., Vivot E., Cruañes M.C., Muñoz J.D.D., Cruañes J., Ferraro G., Gutkind G., Martino V. Antimicrobial activity of Argentine plants used in the treatment of infectious diseases. Isolation of active compounds from Sebastiania brasiliensis. J. Ethnopharmacol. 2001;77:37-40.
Not in our library10.1016/s0378-8741(01)00266-5
129.
Zhang X., Hung T.M., Phuong P.T., Ngoc T.M., Min B.S., Song K.S., Seong Y.H., Bae K. Anti-inflammatory activity of flavonoids from Populus davidiana. Arch. Pharmacal Res. 2006;29:1102-1108.
Not in our library10.1007/bf02969299
130.
Li J., Huang H., Zhou W., Feng M., Zhou P. Anti-hepatitis B virus activities of Geranium carolinianum L. extracts and identification of the active components. Biol. Pharm. Bull. 2008;31:743-747.
Not in our library10.1248/bpb.31.743
131.
Gayosso-De-Lucio J.A., Torres-Valencia J.M., Cerda-García-Rojas C.M., Joseph-Nathan P. Ellagitannins from Geranium potentillaefolium and G. bellum. Nat. Prod. Commun. 2010;5:1934578X1000500407.
Not in our library10.1177/1934578x1000500407
132.
Şeker M.E., Ay E., Aktaş Karaçelik A., Hüseyinoǧlu R., Efe D. First determination of some phenolic compounds and antimicrobial activities of Geranium ibericum subsp. jubatum: A plant endemic to Turkey. Turk. J. Chem. 2021;45:60-70.
Not in our library10.3906/kim-2005-38
133.
Williams C.A., Harborne J.B., Newman M., Greenham J., Eagles J. Chrysin and other leaf exudate flavonoids in the genus Pelargonium. Phytochemistry. 1997;46:1349-1353.
Not in our library10.1016/s0031-9422(97)00514-1
134.
Rochfort S.J., Imsic M., Jones R., Trenerry V.C., Tomkins B. Characterization of flavonol conjugates in immature leaves of pak choi [Brassica rapa L. Ssp. chinensis L. (Hanelt.)] by HPLC-DAD and LC-MS/MS. J. Agric. Food Chem. 2006;54:4855-4860.
Not in our library10.1021/jf060154j
135.
Bennett R.N., Rosa E.A., Mellon F.A., Kroon P.A. Ontogenic profiling of glucosinolates, flavonoids, and other secondary metabolites in Eruca sativa (salad rocket), Diplotaxis erucoides (wall rocket), Diplotaxis tenuifolia (wild rocket), and Bunias orientalis (Turkish rocket). J. Agric. Food Chem. 2006;54:4005-4015.
Not in our library10.1021/jf052756t
136.
Calzada F., Lopéz R., Meckes M., Cedillo-Rivera R. Flavonoids of the Aerial Parts of Helianthemum Glomeratum. Int. J. Pharmacogn. 1995;33:351-352.
Not in our library10.3109/13880209509065393
137.
Papiez M., Gancarczyk M., Bilińska B. The compounds from the hollyhock extract (Althaea rosea Cav. var. nigra) affect the aromatization in rat testicular cells in vivo and in vitro. Folia Histochem. Et Cytobiol. 2002;40:353-359.
Not in our library
138.
Yang H., Protiva P., Cui B., Ma C., Baggett S., Hequet V., Mori S., Weinstein I.B., Kennelly E.J. New Bioactive Polyphenols from Theobroma g randiflorum (“Cupuaçu”). J. Nat. Prod. 2003;66:1501-1504.
Not in our library10.1021/np034002j
139.
Viola H., Wolfman C., Levi de Stein M., Wasowski C., Peña C., Medina J.H., Paladini A.C. Isolation of pharmacologically active benzodiazepine receptor ligands from Tilia tomentosa (Tiliaceae). J. Ethnopharmacol. 1994;44:47-53.
Not in our library10.1016/0378-8741(94)90098-1
140.
Martini N.D., Katerere D.R., Eloff J.N. Biological activity of five antibacterial flavonoids from Combretum erythrophyllum (Combretaceae). J. Ethnopharmacol. 2004;93:207-212.
Not in our library10.1016/j.jep.2004.02.030
141.
Calzada F. Additional antiprotozoal constituents from Cuphea pinetorum, a plant used in Mayan traditional medicine to treat diarrhoea. Phytother. Res. 2005;19:725-727.
Not in our library10.1002/ptr.1717
142.
Amakura Y., Yoshimura M., Sugimoto N., Yamazaki T., Yoshida T. Marker Constituents of the Natural Antioxidant Eucalyptus Leaf Extract for the Evaluation of Food Additives. Biosci. Biotechnol. Biochem. 2009;73:1060-1065.
Not in our library10.1271/bbb.80832
143.
Chen K.C., Chuang C.M., Lin L.Y., Chiu W.T., Wang H.E., Hsieh C.L., Tsai T., Peng R.Y. The polyphenolics in the aqueous extract of Psidium guajava kinetically reveal an inhibition model on LDL glycation. Pharm. Biol. 2010;48:23-31.
Not in our library10.3109/13880200903029365
144.
Cai L., Wu C.D. Compounds from Syzygium aromaticum possessing growth inhibitory activity against oral pathogens. J. Nat. Prod. 1996;59:987-990.
Not in our library10.1021/np960451q
145.
van Elswijk D.A., Schobel U.P., Lansky E.P., Irth H., van der Greef J. Rapid dereplication of estrogenic compounds in pomegranate (Punica granatum) using on-line biochemical detection coupled to mass spectrometry. Phytochemistry. 2004;65:233-241.
Not in our library10.1016/j.phytochem.2003.07.001
146.
Tomaino A., Martorana M., Arcoraci T., Monteleone D., Giovinazzo C., Saija A. Antioxidant activity and phenolic profile of pistachio (Pistacia vera L., variety Bronte) seeds and skins. Biochimie. 2010;92:1115-1122.
Not in our library10.1016/j.biochi.2010.03.027
147.
Jung C.H., Kim J.H., Hong M.H., Seog H.M., Oh S.H., Lee P.J., Kim G.J., Kim H.M., Um J.Y., Ko S.-G. Phenolic-rich fraction from Rhus verniciflua Stokes (RVS) suppress inflammatory response via NF-κB and JNK pathway in lipopolysaccharide-induced RAW 264.7 macrophages. J. Ethnopharmacol. 2007;110:490-497.
Not in our library10.1016/j.jep.2006.10.013
148.
Abou-Shoer M., Ma G.E., Li X.H., Koonchanok N.M., Geahlen R.L., Chang C.J. Flavonoids from Koelreuteria henryi and other sources as protein-tyrosine kinase inhibitors. J. Nat. Prod. 1993;56:967-969.
Not in our library10.1021/np50096a027
149.
Lin W.H., Deng Z.W., Lei H.M., Fu H.Z., Li J. Polyphenolic compounds from the leaves of Koelreuteria paniculata Laxm. J. Asian Nat. Prod. Res. 2002;4:287-295.
Not in our library10.1080/1028602021000049087
150.
Arriaga A.C., de Mesquita A.C., Pouliquen Y.B., de Lima R.A., Cavalcante S.H., de Carvalho M.G., de Siqueira J.A., Alegrio L.V., Braz-Filho R. Chemical constituents of Simarouba versicolor. An. Da Acad. Bras. De Ciências. 2002;74:415-424.
Not in our library10.1590/s0001-37652002000300004
151.
Salvador M.J., Ferreira E.O., Mertens-Talcott S.U., De Castro W.V., Butterweck V., Derendorf H., Dias D.A. Isolation and HPLC quantitative analysis of antioxidant flavonoids from Alternanthera tenella Colla. Z. Für Nat. C. 2006;61:19-25.
Not in our library10.1515/znc-2006-1-204
152.
Aung H.H., Chia L.S., Goh N.K., Chia T.F., Ahmed A.A., Pare P.W., Mabry T.J. Phenolic constituents from the leaves of the carnivorous plant Nepenthes gracilis. Fitoterapia. 2002;73:445-447.
Not in our library10.1016/s0367-326x(02)00113-2
153.
Kataoka M., Hirata K., Kunikata T., Ushio S., Iwaki K., Ohashi K., Ikeda M., Kurimoto M. Antibacterial action of tryptanthrin and kaempferol, isolated from the indigo plant (Polygonum tinctorium Lour.), against Helicobacter pylori-infected Mongolian gerbils. J. Gastroenterol. 2001;36:5-9.
Not in our library10.1007/s005350170147
154.
Parveen Z., Deng Y., Saeed M.K., Dai R., Ahamad W., Yu Y.H. Antiinflammatory and analgesic activities of Thesium chinense Turcz extracts and its major flavonoids, kaempferol and kaempferol-3-O-glucoside. Yakugaku Zasshi. J. Pharm. Soc. Jpn. 2007;127:1275-1279.
Not in our library10.1248/yakushi.127.1275
155.
Loizzo M.R., Said A., Tundis R., Hawas U.W., Rashed K., Menichini F., Frega N.G., Menichini F. Antioxidant and antiproliferative activity of Diospyros lotus L. extract and isolated compounds. Plant Foods Hum. Nutr. 2009;64:264-270.
Not in our library10.1007/s11130-009-0133-0
156.
Crublet M.-L., Long C., Sévenet T., Hadi H.A., Lavaud C. Acylated flavonol glycosides from leaves of Planchonia grandis. Phytochemistry. 2003;64:589-594.
Not in our library10.1016/s0031-9422(03)00215-2
157.
Sumino M., Sekine T., Ruangrungsi N., Igarashi K., Ikegami F. Ardisiphenols and other antioxidant principles from the fruits of Ardisia colorata. Chem. Pharm. Bull. 2002;50:1484-1487.
Not in our library10.1248/cpb.50.1484
158.
Chien M.M., Svoboda G.H., Schiff P.L., Slatkin D.J., Knapp J.E. Chemical constituents of Echites hirsuta (Apocynaceae). J. Pharm. Sci. 1979;68:247-249.
Not in our library10.1002/jps.2600680236
159.
Deng S., Palu K., West B.J., Su C.X., Zhou B.N., Jensen J.C. Lipoxygenase inhibitory constituents of the fruits of noni (Morinda citrifolia) collected in Tahiti. J. Nat. Prod. 2007;70:859-862.
Not in our library10.1021/np0605539
160.
Cimanga R.K., Kambu K., Tona L., Hermans N., Apers S., Totté J., Pieters L., Vlietinck A.J. Cytotoxicity and in vitro susceptibility of Entamoeba histolytica to Morinda morindoides leaf extracts and its isolated constituents. J. Ethnopharmacol. 2006;107:83-90.
Not in our library10.1016/j.jep.2006.02.010
161.
Majinda R.R., Motswaledi M., Waigh R.D., Waterman P.G. Phenolic and antibacterial constituents of Vahlia capensis. Planta Med. 1997;63:268-270.
Not in our library10.1055/s-2006-957671
162.
Ye M., Yan Y., Guo D.A. Characterization of phenolic compounds in the Chinese herbal drug Tu-Si-Zi by liquid chromatography coupled to electrospray ionization mass spectrometry. Rapid Commun. Mass Spectrom. 2005;19:1469-1484.
Not in our library10.1002/rcm.1944
163.
Umehara K., Nemoto K., Ohkubo T., Miyase T., Degawa M., Noguchi H. Isolation of a new 15-membered macrocyclic glycolipid lactone, Cuscutic Resinoside a from the seeds of Cuscuta chinensis: A stimulator of breast cancer cell proliferation. Planta Med. 2004;70:299-304.
Not in our library10.1055/s-2004-818939
164.
Huang H.-C., Syu K.-Y., Lin J.-K. Chemical Composition of Solanum nigrum Linn Extract and Induction of Autophagy by Leaf Water Extract and Its Major Flavonoids in AU565 Breast Cancer Cells. J. Agric. Food Chem. 2010;58:8699-8708.
Not in our library10.1021/jf101003v
165.
Kwak J.H., Kang M.W., Roh J.H., Choi S.U., Zee O.P. Cytotoxic phenolic compounds from Chionanthus retusus. Arch. Pharmacal Res. 2009;32:1681-1687.
Not in our library10.1007/s12272-009-2203-0
166.
de Laurentis N., Stefanizzi L., Milillo M.A., Tantillo G. Flavonoids from leaves of Olea europaea L. cultivars. Ann. Pharm. Françaises. 1998;56:268-273.
Not in our library
167.
Youssef F.S., Altyar A.E., Omar A.M., Ashour M.L. Phytoconstituents, In Vitro Anti-Infective Activity of Buddleja indica Lam., and In Silico Evaluation of its SARS-CoV-2 Inhibitory Potential. Front. Pharmacol. 2021;12:619373.
Not in our library10.3389/fphar.2021.619373
168.
Chatzopoulou A., Karioti A., Gousiadou C., Lax Vivancos V., Kyriazopoulos P., Golegou S., Skaltsa H. Depsides and Other Polar Constituents from Origanum dictamnus L. and Their in Vitro Antimicrobial Activity in Clinical Strains. J. Agric. Food Chem. 2010;58:6064-6068.
Not in our library10.1021/jf904596m
169.
Bai N., He K., Roller M., Lai C.S., Shao X., Pan M.H., Ho C.T. Flavonoids and phenolic compounds from Rosmarinus officinalis. J. Agric. Food Chem. 2010;58:5363-5367.
Not in our library10.1021/jf100332w
170.
Sharififar F., Yassa N., Mozaffarian V. Bioactivity of major components from the seeds of Bunium persicum (Boiss.) Fedtch. Pak. J. Pharm. Sci. 2010;23:300-304.
Not in our library
171.
Pistelli L., Noccioli C., Giachi I., Dimitrova B., Gevrenova R., Morelli I., Potenza D. Lupane-triterpenes from Bupleurum flavum. Nat. Prod. Res. 2005;19:783-788.
Not in our library10.1080/14786410500045119
172.
Guo S., Guo R., Xia Y., Dong T., Wang H., Zhan H. Quantitative analysis of fermented aerial part of Bupleurum chinense and prediction of their antimicrobial activity. Zhongguo Zhong Yao Za Zhi. 2020;45:4238-4245.
Not in our library10.19540/j.cnki.cjcmm.20200622.305
173.
Haraguchi H., Ishikawa H., Sanchez Y., Ogura T., Kubo Y., Kubo I. Antioxidative constituents in Heterotheca inuloides. Bioorganic Med. Chem. 1997;5:865-871.
Not in our library10.1016/s0968-0896(97)00029-1
174.
Hidalgo Báez D., de los Ríos C., Crescente O., Caserta A. Antibacterial and chemical evaluation of Chromolaena moritziana. J. Ethnopharmacol. 1998;59:203-206.
Not in our library10.1016/s0378-8741(97)00111-6
175.
Zhang Y., Zhao L., Shi Y.-P. Separation and Determination of Flavonoids in Ixeridium gracile by Capillary Electrophoresis. J. Chromatogr. Sci. 2007;45:600-604.
Not in our library10.1093/chromsci/45.9.600
176.
Kim D.K. Antioxidative components from the aerial parts of Lactuca scariola L. Arch. Pharmacal Res. 2001;24:427-430.
Not in our library10.1007/bf02975189
177.
Choi S.Z., Choi S.U., Lee K.R. Phytochemical constituents of the aerial parts from Solidago virga-aurea var. gigantea. Arch. Pharmacal Res. 2004;27:164-168.
Not in our library10.1007/bf02980100
178.
Süzgeç S., Meriçli A.H., Houghton P.J., Cubukçu B. Flavonoids of Helichrysum compactum and their antioxidant and antibacterial activity. Fitoterapia. 2005;76:269-272.
Not in our library10.1016/j.fitote.2004.12.006
179.
Maas M., Hensel A., Costa F.B., Brun R., Kaiser M., Schmidt T.J. An unusual dimeric guaianolide with antiprotozoal activity and further sesquiterpene lactones from Eupatoriumperfoliatum. Phytochemistry. 2011;72:635-644.
Not in our library10.1016/j.phytochem.2011.01.025
180.
Prasasty V.D., Cindana S., Ivan F.X., Zahroh H., Sinaga E. Structure-based discovery of novel inhibitors of Mycobacterium tuberculosis CYP121 from Indonesian natural products. Comput. Biol. Chem. 2020;85:107205.
Not in our library10.1016/j.compbiolchem.2020.107205
181.
Schmitzer V., Veberic R., Slatnar A., Stampar F. Elderberry (Sambucus nigra L.) wine: A product rich in health promoting compounds. J. Agric. Food Chem. 2010;58:10143-10146.
Not in our library10.1021/jf102083s
182.
Li M.M., Wang K., Pan Z.H., Chen X.Q., Peng L.Y., Li Y., Cheng X., Zhao Q.S. Two new sesquiterpene glucosides from Dennstaedtia scabra (Wall.) Moore. Chem. Pharm. Bull. 2009;57:1123-1125.
Not in our library10.1248/cpb.57.1123
183.
Lin Y.L., Shen C.C., Huang Y.J., Chang Y.Y. Homoflavonoids from Ophioglossum petiolatum. J. Nat. Prod. 2005;68:381-384.
Not in our library10.1021/np0401819
184.
Bhagwat S., Haytowitz D.B., Holden J.M. USDA Database for the Flavonoid Content of Selected Foods. 2011.
Not in our library
185.
Fieschi M., Codignola A., Luppi Mosca A.M. Mutagenic Flavonol Aglycones in Infusions and in Fresh and Pickled Vegetables. J. Food Sci. 1989;54:1492-1495.
Not in our library10.1111/j.1365-2621.1989.tb05143.x
186.
Miean K.H., Mohamed S. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J. Agric. Food Chem. 2001;49:3106-3112.
Not in our library10.1021/jf000892m
187.
Herrmann K. Flavonols and flavones in food plants: A review†. Int. J. Food Sci. Technol. 1976;11:433-448.
Not in our library10.1111/j.1365-2621.1976.tb00743.x
188.
Häkkinen S.H., Kärenlampi S.O., Heinonen I.M., Mykkänen H.M., Törrönen A.R. Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries. J. Agric. Food Chem. 1999;47:2274-2279.
Not in our library10.1021/jf9811065
189.
Wallace R.J. Antimicrobial properties of plant secondary metabolites. Proc. Nutr. Soc. 2004;63:621-629.
Not in our library10.1079/pns2004393
190.
Kaspar F., Neubauer P., Gimpel M. Bioactive Secondary Metabolites from Bacillus subtilis: A Comprehensive Review. J. Nat. Prod. 2019;82:2038-2053.
Not in our library10.1021/acs.jnatprod.9b00110
191.
Piper Species: A Comprehensive Review on Their Phytochemistry, Biological Activities and Applications · 2019
No notice
192.
Makuwa S.C., Serepa-Dlamini M.H. The Antibacterial Activity of Crude Extracts of Secondary Metabolites from Bacterial Endophytes Associated with Dicoma anomala. Int. J. Microbiol. 2021;2021:8812043.
Not in our library10.1155/2021/8812043
193.
Secondary metabolite compounds from Sida genus and their bioactivity · 2021
Not checked
194.
Review on the Antibacterial Mechanism of Plant-Derived Compounds against Multidrug-Resistant Bacteria (MDR) · 2021
No notice
195.
Bhatia P., Sharma A., George A.J., Anvitha D., Kumar P., Dwivedi V.P., Chandra N.S. Antibacterial activity of medicinal plants against ESKAPE: An update. Heliyon. 2021;7:e06310.
Not in our library10.1016/j.heliyon.2021.e06310
196.
Popescu G.A., Șerban R., Iosif I., Codiță I., Dorobăț O., Tălăpan D., Buzea M., Szekely E., Dorneanu O., Bota K., et al. Antimicrobial resistance of germs isolated from invasive infections—Romania 2012. BMC Infect. Dis. 2013;13:O16.
Not in our library10.1186/1471-2334-13-s1-o16
197.
Rafila A., Tălăpan D., Dorobat O., Popescu G., Piţigoi D., Florea D., Buicu F. Emergence of Carbapenemase-producing Enterobacteriaceae, a Public Health Threat: A Romanian Infectious Disease Hospital Based Study. Rev. Romana De Med. De Lab. 2015;23:295-301.
Not in our library10.1515/rrlm-2015-0024
198.
Tălăpan D., Rafila A. Five-Year Survey of Asymptomatic Colonization with Multidrug-Resistant Organisms in a Romanian Tertiary Care Hospital. Infect. Drug Resist. 2022;15:2959-2967.
Not in our library10.2147/idr.s360048
199.
Liu H., Orjala J., Sticher O., Rali T. Acylated flavonol glycosides from leaves of Stenochlaena palustris. J. Nat. Prod. 1999;62:70-75.
Not in our library10.1021/np980179f
200.
Li X.-M., Luo X.-G., Si C.-L., Wang N., Zhou H., He J.-F., Zhang T.-C. Antibacterial active compounds from Hypericum ascyron L. induce bacterial cell death through apoptosis pathway. Eur. J. Med. Chem. 2015;96:436-444.
Not in our library10.1016/j.ejmech.2015.04.035
201.
He M., Wu T., Pan S., Xu X. Antimicrobial mechanism of flavonoids against Escherichia coli ATCC 25922 by model membrane study. Appl. Surf. Sci. 2014;305:515-521.
Not in our library10.1016/j.apsusc.2014.03.125
202.
Cronan J.E., Thomas J. Bacterial fatty acid synthesis and its relationships with polyketide synthetic pathways. Methods Enzymol. 2009;459:395-433.
Not in our library10.1016/s0076-6879(09)04617-5
203.
Rowlett V.W., Mallampalli V., Karlstaedt A., Dowhan W., Taegtmeyer H., Margolin W., Vitrac H. Impact of Membrane Phospholipid Alterations in Escherichia coli on Cellular Function and Bacterial Stress Adaptation. J. Bacteriol. 2017;199:e00849-16.
Not in our library10.1128/jb.00849-16
204.
Al-Nour M.Y., Ibrahim M.M., Elsaman T. Ellagic Acid, Kaempferol, and Quercetin from Acacia nilotica: Promising Combined Drug With Multiple Mechanisms of Action. Curr. Pharmacol. Rep. 2019;5:255-280.
Not in our library10.1007/s40495-019-00181-w
205.
Wu T., Zang X., He M., Pan S., Xu X. Structure-activity relationship of flavonoids on their anti-Escherichia coli activity and inhibition of DNA gyrase. J. Agric. Food Chem. 2013;61:8185-8190.
Not in our library10.1021/jf402222v
206.
Liu M.H., Otsuka N., Noyori K., Shiota S., Ogawa W., Kuroda T., Hatano T., Tsuchiya T. Synergistic effect of kaempferol glycosides purified from Laurus nobilis and fluoroquinolones on methicillin-resistant Staphylococcus aureus. Biol. Pharm. Bull. 2009;32:489-492.
Not in our library10.1248/bpb.32.489
207.
Huang Y.H., Huang C.C., Chen C.C., Yang K.J., Huang C.Y. Inhibition of Staphylococcus aureus PriA Helicase by Flavonol Kaempferol. Protein. J. 2015;34:169-172.
Not in our library10.1007/s10930-015-9609-y
208.
Lim Y.H., Kim I.H., Seo J.J. In vitro activity of kaempferol isolated from the Impatiens balsamina alone and in combination with erythromycin or clindamycin against Propionibacterium acnes. J. Microbiol. 2007;45:473-477.
Not in our library
209.
Christopoulou C., Graikou K., Chinou I. Chemosystematic Value of Chemical Constituents from Scabiosa hymettia (Dipsacaceae). Chem. Biodivers. 2008;5:318-323.
Not in our library10.1002/cbdv.200890029
210.
Ragasa C.Y., de Luna R.D., Cruz W.C., Rideout J.A. Monoterpene Lactones from the Seeds of Nephelium lappaceum. J. Nat. Prod. 2005;68:1394-1396.
Not in our library10.1021/np0580053
211.
Phytochemical Analysis and Antimicrobial Activities of Methanolic Extracts of Leaf, Stem and Root from Different Varieties of Labisa pumila Benth · 2011
Not checked
212.
Achika J.I., Ayo R.G., Oyewale A.O., Habila J.D. Flavonoids with antibacterial and antioxidant potentials from the stem bark of Uapaca heudelotti. Heliyon. 2020;6:e03381.
Not in our library10.1016/j.heliyon.2020.e03381
213.
de Freitas M.A., da Cruz R.P., Dos Santos A.T.L., Almeida-Bezerra J.W., Machado A.J.T., Dos Santos J.F.S., Rocha J.E., Boligon A.A., Bezerra C.F., de Freitas T.S., et al. HPLC-DAD analysis and antimicrobial activities of Spondias mombin L. (Anacardiaceae). 3 Biotech. 2022;12:61.
Not in our library10.1007/s13205-022-03126-1
214.
Özçelik B., Orhan I., Toker G. Antiviral and Antimicrobial Assessment of Some Selected Flavonoids. Z. Für Nat. C. 2006;61:632-638.
Not in our library10.1515/znc-2006-9-1003
215.
Rofeal M., El-Malek F.A., Qi X. In vitro assessment of green polyhydroxybutyrate/chitosan blend loaded with kaempferol nanocrystals as a potential dressing for infected wounds. Nanotechnology. 2021;32:37.
Not in our library10.1088/1361-6528/abf7ee
216.
Šuran J., Cepanec I., Mašek T., Starčević K., Tlak Gajger I., Vranješ M., Radić B., Radić S., Kosalec I., Vlainić J. Nonaqueous Polyethylene Glycol as a Safer Alternative to Ethanolic Propolis Extracts with Comparable Antioxidant and Antimicrobial Activity. Antioxidants. 2021;10:978.
Not in our library10.3390/antiox10060978
217.
Kannanoor M., Lakshmi B.A., Kim S. Synthesis of silver nanoparticles conjugated with kaempferol and hydrocortisone and an evaluation of their antibacterial effects. 3 Biotech. 2021;11:317.
Not in our library10.1007/s13205-021-02880-y
218.
Galal T.M., Al-Yasi H.M., Fawzy M.A., Abdelkader T.G., Hamza R.Z., Eid E.M., Ali E.F. Evaluation of the Phytochemical and Pharmacological Potential of Taif’s Rose (Rosa damascena Mill var. trigintipetala) for Possible Recycling of Pruning Wastes. Life. 2022;12:273.
Not in our library10.3390/life12020273
219.
Attallah N.G.M., El-Sherbeni S.A., El-Kadem A.H., Elekhnawy E., El-Masry T.A., Elmongy E.I., Altwaijry N., Negm W.A. Elucidation of the Metabolite Profile of Yucca gigantea and Assessment of Its Cytotoxic, Antimicrobial, and Anti-Inflammatory Activities. Molecules. 2022;27:1329.
Not in our library10.3390/molecules27041329
220.
Habbu P.V., Mahadevan K.M., Shastry R.A., Manjunatha H. Antimicrobial activity of flavanoid sulphates and other fractions of Argyreia speciosa (Burm.f) Boj. Indian J. Exp. Biol. 2009;47:121-128.
Not in our library
221.
Antimicrobial and antioxidant activity of kaempferol rhamnoside derivatives from Bryophyllum pinnatum · 2012
No notice
222.
Otsuka N., Liu M.H., Shiota S., Ogawa W., Kuroda T., Hatano T., Tsuchiya T. Anti-methicillin resistant Staphylococcus aureus (MRSA) compounds isolated from Laurus nobilis. Biol. Pharm. Bull. 2008;31:1794-1797.
Not in our library10.1248/bpb.31.1794
223.
Bisignano G., Sanogo R., Marino A., Aquino R., D’Angelo V., Germanò M.P., De Pasquale R., Pizza C. Antimicrobial activity of Mitracarpus scaber extract and isolated constituents. Lett. Appl. Microbiol. 2000;30:105-108.
Not in our library10.1046/j.1472-765x.2000.00692.x
224.
Ivanova A., Mikhova B., Najdenski H., Tsvetkova I., Kostova I. Chemical composition and antimicrobial activity of wild garlic Allium ursinum of Bulgarian origin. Nat. Prod. Commun. 2009;4:1059-1062.
Not in our library10.1177/1934578x0900400808
225.
Ibrahim M.A., Mansoor A.A., Gross A., Ashfaq M.K., Jacob M., Khan S.I., Hamann M.T. Methicillin-resistant Staphylococcus aureus (MRSA)-active metabolites from Platanus occidentalis (American Sycamore). J. Nat. Prod. 2009;72:2141-2144.
Not in our library10.1021/np900499q
226.
Chan E.W., Gray A.I., Igoli J.O., Lee S.M., Goh J.K. Galloylated flavonol rhamnosides from the leaves of Calliandra tergemina with antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA). Phytochemistry. 2014;107:148-154.
Not in our library10.1016/j.phytochem.2014.07.028
227.
Zhang Y., Valeriote F., Swartz K., Chen B., Hamann M.T., Rodenburg D.L., McChesney J.D., Shaw J. HPLC Plasma Assay of a Novel Anti-MRSA Compound, Kaempferol-3-O-Alpha-L-(2”,3”-di-p-coumaroyl)rhamnoside, from Sycamore Leaves. Nat. Prod. Commun. 2015;10:1383-1386.
Not in our library10.1177/1934578x1501000818
228.
Carruthers N.J., Stemmer P.M., Media J., Swartz K., Wang X., Aube N., Hamann M.T., Valeriote F., Shaw J. The anti-MRSA compound 3-O-alpha-L-(2″,3″-di-p-coumaroyl)rhamnoside (KCR) inhibits protein synthesis in Staphylococcus aureus. J. Proteom. 2020;210:103539.
Not in our library10.1016/j.jprot.2019.103539
229.
Ishikawa R.B., Leitão M.M., Kassuya R.M., Macorini L.F., Moreira F.M.F., Cardoso C.A.L., Coelho R.G., Pott A., Gelfuso G.M., Croda J., et al. Anti-inflammatory, antimycobacterial and genotoxic evaluation of Doliocarpus dentatus. J. Ethnopharmacol. 2017;204:18-25.
Not in our library10.1016/j.jep.2017.04.004
230.
Santos E.D., Silva-Filho S.E., Santos Radai J.A., Arena A.C., Fraga T.L., Lima Cardoso C.A., Croda J., Leite Kassuya C.A. Anti-inflammatory properties of ethanolic extract from Vatairea macrocarpa leaves. J. Ethnopharmacol. 2021;278:114308.
Not in our library10.1016/j.jep.2021.114308
231.
Asif M., Alvi I.A., Rehman S.U. Insight into Acinetobacter baumannii: Pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect. Drug Resist. 2018;11:1249-1260.
Not in our library10.2147/idr.s166750
232.
Pourhajibagher M., Hashemi F.B., Pourakbari B., Aziemzadeh M., Bahador A. Antimicrobial Resistance of Acinetobacter baumannii to Imipenem in Iran: A Systematic Review and Meta-Analysis. Open Microbiol J. 2016;10:32-42.
Not in our library10.2174/1874285801610010032
233.
Relationship between Antibiotic Resistance, Biofilm Formation, and Biofilm-Specific Resistance in Acinetobacter baumannii · 2016
No notice
234.
Gheorghe-Barbu I., Barbu I.C., Popa L.I., Pîrcălăbioru G.G., Popa M., Măruțescu L., Niță-Lazar M., Banciu A., Stoica C., Gheorghe Ș., et al. Temporo-spatial variations in resistance determinants and clonality of Acinetobacter baumannii and Pseudomonas aeruginosa strains from Romanian hospitals and wastewaters. Antimicrob. Resist. Infect. Control. 2022;11:115.
Not in our library10.1186/s13756-022-01156-1
235.
A First Study of the Virulence Potential of a Bacillus subtilis Isolate From Deep-Sea Hydrothermal Vent · 2019
Not checked
236.
Cote C.K., Heffron J.D., Bozue J.A., Welkos S.L., Tang Y.-W., Sussman M., Liu D., Poxton I., Schwartzman J. Chapter 102—Bacillus anthracis and Other Bacillus Species. Molecular Medical Microbiology. 2015;1789-1844.
Not in our library10.1016/b978-0-12-397169-2.00102-5
237.
Brown K.L. Control of bacterial spores. Br. Med. Bull. 2000;56:158-171.
Not in our library10.1258/0007142001902860
238.
Spencer R.C. Bacillus anthracis. J. Clin. Pathol. 2003;56:182-187.
Not in our library10.1136/jcp.56.3.182
239.
Hoffmaster A.R., Hill K.K., Gee J.E., Marston C.K., De B.K., Popovic T., Sue D., Wilkins P.P., Avashia S.B., Drumgoole R., et al. Characterization of Bacillus cereus isolates associated with fatal pneumonias: Strains are closely related to Bacillus anthracis and harbor B. anthracis virulence genes. J. Clin. Microbiol. 2006;44:3352-3360.
Not in our library10.1128/jcm.00561-06
240.
The Pore-Forming Haemolysins of Bacillus Cereus: A Review · 2013
No notice
241.
Kaper J.B., Nataro J.P., Mobley H.L.T. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2004;2:123-140.
Not in our library10.1038/nrmicro818
242.
Nataro J.P., Kaper J.B. Diarrheagenic Escherichia coli. Clin. Microbiol. Rev. 1998;11:142-201.
Not in our library10.1128/cmr.11.1.142
243.
Prevalence of integron classes in Gram-negative clinical isolated bacteria in Iran: a systematic review and meta-analysis · 2019
Not checked
244.
Klebsiella pneumoniae: an increasing threat to public health · 2020
No notice
245.
Navon-Venezia S., Kondratyeva K., Carattoli A. Klebsiella pneumoniae: A major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol. Rev. 2017;41:252-275.
Not in our library10.1093/femsre/fux013
246.
Podschun R., Ullmann U. Klebsiella spp. as nosocomial pathogens: Epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin. Microbiol. Rev. 1998;11:589-603.
Not in our library10.1128/cmr.11.4.589
247.
Surleac M., Barbu I., Paraschiv S., Popa L., Gheorghe I., Marutescu L., Popa M., Avram I., Tălăpan D., Nita-Lazar M., et al. Whole genome sequencing snapshot of multi-drug resistant Klebsiella pneumoniae strains from hospitals and receiving wastewater treatment plants in Southern Romania. PLoS ONE. 2020;15:e0228079.
Not in our library10.1371/journal.pone.0228079
248.
Popa L., Gheorghe I., Barbu I., Surleac M., Paraschiv S., Marutescu L., Popa M., Gradisteanu Pircalabioru G., Tălăpan D., Nita-Lazar M., et al. Multidrug Resistant Klebsiella pneumoniae ST101 Clone Survival Chain From Inpatients to Hospital Effluent After Chlorine Treatment. Front. Microbiol. 2021;11:610296.
Not in our library10.3389/fmicb.2020.610296
249.
Smith I. Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. Clin. Microbiol. Rev. 2003;16:463-496.
Not in our library10.1128/cmr.16.3.463-496.2003
250.
Mangtani P., Abubakar I., Ariti C., Beynon R., Pimpin L., Fine P.E., Rodrigues L.C., Smith P.G., Lipman M., Whiting P.F., et al. Protection by BCG vaccine against tuberculosis: A systematic review of randomized controlled trials. Clin. Infect. Dis. 2014;58:470-480.
Not in our library10.1093/cid/cit790
251.
Scriba T.J., Netea M.G., Ginsberg A.M. Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis. Semin. Immunol. 2020;50:101431.
Not in our library10.1016/j.smim.2020.101431
252.
Popescu G.G., Arghir O.C., Fildan A.P., Spanu V., Cambrea S.C., Rafila A., Buicu F.C. Antibiotic resistance of Mycobacterium tuberculosis; mechanism and specific therapeutic response. Farmacia. 2020;68:197-205.
Not in our library10.31925/farmacia.2020.2.2
253.
Evolution of Drug-Resistant Mycobacterium tuberculosis Strains and Their Adaptation to the Human Lung Environment · 2021
No notice
254.
Spratt B.G. Antibiotic resistance: Counting the cost. Curr. Biol. 1996;6:1219-1221.
Not in our library10.1016/s0960-9822(96)00700-2
255.
Böttger E.C., Springer B., Pletschette M., Sander P. Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat. Med. 1998;4:1343-1344.
Not in our library10.1038/3906
256.
Andersson D.I., Levin B.R. The biological cost of antibiotic resistance. Curr. Opin. Microbiol. 1999;2:489-493.
Not in our library10.1016/s1369-5274(99)00005-3
257.
Fanning A., Edwards S. Mycobacterium bovis infection in human beings in contact with elk (Cervus elaphus) in Alberta, Canada. Lancet. 1991;338:1253-1255.
Not in our library10.1016/0140-6736(91)92113-g
258.
Cooke M.M., Gear A.J., Naidoo A., Collins D.M. Accidental Mycobacterium bovis infection in a veterinarian. New Zealand Vet. J. 2002;50:36-38.
Not in our library10.1080/00480169.2002.36248
259.
Wilkins M., Bartlett P., Frawley B., O’Brien D., Miller C., Boulton M. Mycobacterium bovis (bovine TB) exposure as a recreational risk for hunters: Results of a Michigan Hunter Survey, 2001. Int. J. Tuberc. Lung Dis. 2003;7:1001-1009.
Not in our library
260.
Wilkins M.J., Meyerson J., Bartlett P.C., Spieldenner S.L., Berry D.E., Mosher L.B., Kaneene J.B., Robinson-Dunn B., Stobierski M.G., Boulton M.L. Human Mycobacterium bovis infection and bovine tuberculosis outbreak, Michigan, 1994–2007. Emerg. Infect. Dis. 2008;14:657.
Not in our library10.3201/eid1404.070408
261.
Palmer M.V., Thacker T.C., Waters W.R., Gortázar C., Corner L.A.L. Mycobacterium bovis: A Model Pathogen at the Interface of Livestock, Wildlife, and Humans. Vet. Med. Int. 2012;2012:236205.
Not in our library10.1155/2012/236205
262.
Di Chiara J.M., Contreras-Martinez L.M., Livny J., Smith D., McDonough K.A., Belfort M. Multiple small RNAs identified in Mycobacterium bovis BCG are also expressed in Mycobacterium tuberculosis and Mycobacterium smegmatis. Nucleic Acids Res. 2010;38:4067-4078.
Not in our library10.1093/nar/gkq101
263.
Recent advances in understanding Pseudomonas aeruginosa as a pathogen · 2017
No notice
264.
Buhl M., Peter S., Willmann M. Prevalence and risk factors associated with colonization and infection of extensively drug-resistant Pseudomonas aeruginosa: A systematic review. Expert Rev. Anti Infect. Ther. 2015;13:1159-1170.
Not in our library10.1586/14787210.2015.1064310
265.
Murphy T.F. Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease. Curr. Opin. Pulm. Med. 2009;15:138-142.
Not in our library10.1097/mcp.0b013e328321861a
266.
Gonçalves-de-Albuquerque C.F., Silva A.R., Burth P., Rocco P.R., Castro-Faria M.V., Castro-Faria-Neto H.C. Possible mechanisms of Pseudomonas aeruginosa-associated lung disease. Int. J. Med. Microbiol. 2016;306:20-28.
Not in our library10.1016/j.ijmm.2015.11.001
267.
Talwalkar J.S., Murray T.S. The Approach to Pseudomonas aeruginosa in Cystic Fibrosis. Clin. Chest Med. 2016;37:69-81.
Not in our library10.1016/j.ccm.2015.10.004
268.
Pseudomonas aeruginosa Evolutionary Adaptation and Diversification in Cystic Fibrosis Chronic Lung Infections · 2016
No notice
269.
Willcox M.D. Pseudomonas aeruginosa infection and inflammation during contact lens wear: A review. Optom. Vis. Sci. 2007;84:273-278.
Not in our library10.1097/opx.0b013e3180439c3e
270.
Church D., Elsayed S., Reid O., Winston B., Lindsay R. Burn wound infections. Clin. Microbiol. Rev. 2006;19:403-434.
Not in our library10.1128/cmr.19.2.403-434.2006
271.
Fournier A., Voirol P., Krähenbühl M., Bonnemain C.L., Fournier C., Pantet O., Pagani J.L., Revelly J.P., Dupuis-Lozeron E., Sadeghipour F., et al. Antibiotic consumption to detect epidemics of Pseudomonas aeruginosa in a burn centre: A paradigm shift in the epidemiological surveillance of Pseudomonas aeruginosa nosocomial infections. Burns. 2016;42:564-570.
Not in our library10.1016/j.burns.2015.10.030
272.
Döring G., Parameswaran I.G., Murphy T.F. Differential adaptation of microbial pathogens to airways of patients with cystic fibrosis and chronic obstructive pulmonary disease. FEMS Microbiol. Rev. 2011;35:124-146.
Not in our library10.1111/j.1574-6976.2010.00237.x
273.
Langan K.M., Kotsimbos T., Peleg A.Y. Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis. Curr. Opin. Infect. Dis. 2015;28:547-556.
Not in our library10.1097/qco.0000000000000217
274.
Bassi G.L., Ferrer M., Marti J.D., Comaru T., Torres A. Ventilator-associated pneumonia. Semin. Respir. Crit. Care Med. 2014;35:469-481.
Not in our library10.1055/s-0034-1384752
275.
Pang Z., Raudonis R., Glick B.R., Lin T.-J., Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies. Biotechnol. Adv. 2019;37:177-192.
Not in our library10.1016/j.biotechadv.2018.11.013
276.
Crump J.A., Luby S.P., Mintz E.D. The global burden of typhoid fever. Bull. World Health Organ. 2004;82:346-353.
Not in our library
277.
Popa G., Popa M.I. Salmonella spp. Infection—A continuous threat worldwide. GERMS. 2021;11:87-96.
Not in our library10.18683/germs.2021.1244
278.
Allerberger F., Liesegang A., Grif K., Khaschabi D., Prager R., Danzl J., Höck F., Ottl J., Dierich M.P., Berghold C., et al. Occurrence of Salmonella enterica serovar Dublin in Austria. Wien Med. Wochenschr. 2003;153:148-152.
Not in our library10.1046/j.1563-258x.2003.03015.x
279.
Eng S.-K., Pusparajah P., Ab Mutalib N.-S., Ser H.-L., Chan K.-G., Lee L.-H. Salmonella: A review on pathogenesis, epidemiology and antibiotic resistance. Front. Life Sci. 2015;8:284-293.
Not in our library10.1080/21553769.2015.1051243
280.
Chiu C.H., Wu T.L., Su L.H., Chu C., Chia J.H., Kuo A.J., Chien M.S., Lin T.Y. The emergence in Taiwan of fluoroquinolone resistance in Salmonella enterica serotype choleraesuis. N. Engl. J. Med. 2002;346:413-419.
Not in our library10.1056/nejmoa012261
281.
Tong S.Y., Davis J.S., Eichenberger E., Holland T.L., Fowler V.G. Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management. Clin. Microbiol. Rev. 2015;28:603-661.
Not in our library10.1128/cmr.00134-14
282.
Sandulescu O., Bleotu C., Matei L., Streinu-Cercel A., Oprea M., Dragulescu E., Chifiriuc M., Rafila A., Pirici D., Tălăpan D., et al. Comparative evaluation of aggressiveness traits in staphylococcal strains from severe infections versus nasopharyngeal carriage. Microb. Pathog. 2016;102:45-53.
Not in our library10.1016/j.micpath.2016.11.006
283.
Malachowa N., DeLeo F.R. Mobile genetic elements of Staphylococcus aureus. Cell Mol. Life Sci. 2010;67:3057-3071.
Not in our library10.1007/s00018-010-0389-4
284.
Howden B.P., Davies J.K., Johnson P.D., Stinear T.P., Grayson M.L. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: Resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 2010;23:99-139.
Not in our library10.1128/cmr.00042-09
285.
Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., Harrison L.H., Lynfield R., Dumyati G., Townes J.M., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA. 2007;298:1763-1771.
Not in our library10.1001/jama.298.15.1763
286.
Durai R., Ng P.C., Hoque H. Methicillin-resistant Staphylococcus aureus: An update. Aorn J. 2010;91:599-606.
Not in our library10.1016/j.aorn.2009.11.065
287.
Johnson A.P. Methicillin-resistant Staphylococcus aureus: The European landscape. J. Antimicrob. Chemother. 2011;66((Suppl. 4)):iv43-iv48.
Not in our library10.1093/jac/dkr076
288.
MRSA prevalence in european healthcare settings: a review · 2011
No notice
289.
Grema H.A., Geidam Y.A., Gadzama G.B., Ameh J.A., Suleiman A. Methicillin resistant Staphylococcus aureus (MRSA): A review. Adv. Anim. Vet. Sci. 2015;3:79-98.
Not in our library10.14737/journal.aavs/2015/3.2.79.98
290.
Otto M. Staphylococcus epidermidis—The ‘accidental’ pathogen. Nat. Rev. Microbiol. 2009;7:555-567.
Not in our library10.1038/nrmicro2182
291.
Schaberg D.R., Culver D.H., Gaynes R.P. Major trends in the microbial etiology of nosocomial infection. Am. J. Med. 1991;91:72s-75s.
Not in our library10.1016/0002-9343(91)90346-y
292.
Kaye D. Enterococci. Biologic and epidemiologic characteristics and in vitro susceptibility. Arch. Intern. Med. 1982;142:2006-2009.
Not in our library10.1001/archinte.1982.00340240028006
293.
Maki D.G., Agger W.A. Enterococcal Bacteremia: Clinical Features, the Risk of Endocarditis, and Management. Medicine. 1988;67:248.
Not in our library10.1097/00005792-198807000-00005
294.
Noskin G.A., Peterson L.R., Warren J.R. Enterococcus faecium and Enterococcus faecalis bacteremia: Acquisition and outcome. Clin. Infect. Dis. 1995;20:296-301.
Not in our library10.1093/clinids/20.2.296
295.
Cetinkaya Y., Falk P., Mayhall C.G. Vancomycin-Resistant Enterococci. Clin. Microbiol. Rev. 2000;13:686-707.
Not in our library10.1128/cmr.13.4.686
296.
Papazafiropoulou A., Daniil I., Sotiropoulos A., Balampani E., Kokolaki A., Bousboulas S., Konstantopoulou S., Skliros E., Petropoulou D., Pappas S. Prevalence of asymptomatic bacteriuria in type 2 diabetic subjects with and without microalbuminuria. BMC Res. Notes. 2010;3:169.
Not in our library10.1186/1756-0500-3-169
297.
Matthews S.J., Lancaster J.W. Urinary tract infections in the elderly population. Am. J. Geriatr. Pharmacother. 2011;9:286-309.
Not in our library10.1016/j.amjopharm.2011.07.002
298.
Schaffer J.N., Pearson M.M. Proteus mirabilis and Urinary Tract Infections. Microbiol. Spectr. 2015;3:3-5.
Not in our library10.1128/microbiolspec.uti-0017-2013
299.
Charkhian H., Bodaqlouie A., Soleimannezhadbari E., Lotfollahi L., Shaykh-Baygloo N., Hosseinzadeh R., Yousefi N., Khodayar M. Comparing the Bacteriostatic Effects of Different Metal Nanoparticles Against Proteus vulgaris. Curr. Microbiol. 2020;77:2674-2684.
Not in our library10.1007/s00284-020-02029-9
300.
Mobley H.L., Warren J.W. Urease-positive bacteriuria and obstruction of long-term urinary catheters. J. Clin. Microbiol. 1987;25:2216-2217.
Not in our library10.1128/jcm.25.11.2216-2217.1987
301.
Mobley H.L., Warren J.W. Urinary Tract Infections: Molecular Pathogenesis and Clinical Management. 1996;3-27.
Not in our library
302.
Jacobsen S.M., Shirtliff M.E. Proteus mirabilis biofilms and catheter-associated urinary tract infections. Virulence. 2011;2:460-465.
Not in our library10.4161/viru.2.5.17783
303.
Yuan F., Huang Z., Yang T., Wang G., Li P., Yang B., Li J. Pathogenesis of Proteus mirabilis in Catheter-Associated Urinary Tract Infections. Urol. Int. 2021;105:354-361.
Not in our library10.1159/000514097
304.
Hall R.M., Collis C.M. Antibiotic resistance in gram-negative bacteria: The role of gene cassettes and integrons. Drug Resist. Updat. 1998;1:109-119.
Not in our library10.1016/s1368-7646(98)80026-5
305.
Tumbarello M., Trecarichi E.M., Fiori B., Losito A.R., D’Inzeo T., Campana L., Ruggeri A., Di Meco E., Liberto E., Fadda G., et al. Multidrug-resistant Proteus mirabilis bloodstream infections: Risk factors and outcomes. Antimicrob. Agents Chemother. 2012;56:3224-3231.
Not in our library10.1128/aac.05966-11
306.
Pagani L., Migliavacca R., Pallecchi L., Matti C., Giacobone E., Amicosante G., Romero E., Rossolini G.M. Emerging extended-spectrum beta-lactamases in Proteus mirabilis. J. Clin. Microbiol. 2002;40:1549-1552.
Not in our library10.1128/jcm.40.4.1549-1552.2002
307.
Endimiani A., Luzzaro F., Brigante G., Perilli M., Lombardi G., Amicosante G., Rossolini G.M., Toniolo A. Proteus mirabilis bloodstream infections: Risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob. Agents Chemother. 2005;49:2598-2605.
Not in our library10.1128/aac.49.7.2598-2605.2005
308.
Cohen-Nahum K., Saidel-Odes L., Riesenberg K., Schlaeffer F., Borer A. Urinary tract infections caused by multi-drug resistant Proteus mirabilis: Risk factors and clinical outcomes. Infection. 2010;38:41-46.
Not in our library10.1007/s15010-009-8460-5
309.
D’Andrea M.M., Literacka E., Zioga A., Giani T., Baraniak A., Fiett J., Sadowy E., Tassios P.T., Rossolini G.M., Gniadkowski M., et al. Evolution and spread of a multidrug-resistant Proteus mirabilis clone with chromosomal AmpC-type cephalosporinases in Europe. Antimicrob. Agents Chemother. 2011;55:2735-2742.
Not in our library10.1128/aac.01736-10
310.
Vaez H., Kalarestaghi H., Sahebkar A., Khademi F. Prevalence of antibiotic resistance of Proteus species in urinary tract infections in Iran: A systematic review and meta-analysis. Gene Rep. 2022;27:101632.
Not in our library10.1016/j.genrep.2022.101632
311.
Colwell R.R., Kaper J., Joseph S.W. Vibrio cholerae, Vibrio parahaemolyticus, and other vibrios: Occurrence and distribution in Chesapeake Bay. Science. 1977;198:394-396.
Not in our library
312.
Garay E., Arnau A., Amaro C. Incidence of Vibrio cholerae and related vibrios in a coastal lagoon and seawater influenced by lake discharges along an annual cycle. Appl. Environ. Microbiol. 1985;50:426-430.
Not in our library10.1128/aem.50.2.426-430.1985
313.
Colwell R.R. Global climate and infectious disease: The cholera paradigm. Science. 1996;274:2025-2031.
Not in our library10.1126/science.274.5295.2025
314.
Reidl J., Klose K.E. Vibrio cholerae and cholera: Out of the water and into the host. FEMS Microbiol. Rev. 2002;26:125-139.
Not in our library10.1111/j.1574-6976.2002.tb00605.x
315.
Glass R.I., Huq I., Alim A.R.M.A., Yunus M. Emergence of Multiply Antibiotic-Resistant Vibrio cholerae in Bangladesh. J. Infect. Dis. 1980;142:939-942.
Not in our library10.1093/infdis/142.6.939
316.
Das B., Verma J., Kumar P., Ghosh A., Ramamurthy T. Antibiotic resistance in Vibrio cholerae: Understanding the ecology of resistance genes and mechanisms. Vaccine. 2020;38:A83-A92.
Not in our library10.1016/j.vaccine.2019.06.031
317.
Brown G.D., Denning D.W., Levitz S.M. Tackling human fungal infections. Science. 2012;336:647.
Not in our library10.1126/science.1222236
318.
Mayer F.L., Wilson D., Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;4:119-128.
Not in our library10.4161/viru.22913
319.
Pfaller M.A., Diekema D.J. Epidemiology of invasive candidiasis: A persistent public health problem. Clin. Microbiol. Rev. 2007;20:133-163.
Not in our library10.1128/cmr.00029-06
320.
Pfaller M.A., Diekema D.J. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 2010;36:1-53.
Not in our library10.3109/10408410903241444
321.
Hurley R., De Louvois J. Candida vaginitis. Postgrad. Med. J. 1979;55:645-647.
Not in our library10.1136/pgmj.55.647.645
322.
Sobel J.D. Vulvovaginal candidosis. Lancet. 2007;369:1961-1971.
Not in our library10.1016/s0140-6736(07)60917-9
323.
Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., Filler S.G., Fisher J.F., Kullberg B.J., Ostrosky-Zeichner L., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2009;48:503-535.
Not in our library10.1086/596757
324.
Fidel P.L. History and new insights into host defense against vaginal candidiasis. Trends Microbiol. 2004;12:220-227.
Not in our library10.1016/j.tim.2004.03.006
325.
Cohen J., Denning D.W., Viviani M.A. Epidemiology of invasive aspergillosis in European cancer centres. EORTC Invasive Fungal Infections Cooperative Group. Eur. J. Clin. Microbiol. Infect. Dis. 1993;12:392-393.
Not in our library10.1007/bf01964440
326.
Rogers T. Epidemiology and control of nosocomial fungal infections. Curr. Opin. Infect. Dis. 1995;8:287-290.
Not in our library10.1097/00001432-199508000-00014
327.
Ruchlemer R., Yinnon A.M., Hershko C. Changes in the natural history of invasive pulmonary aspergillosis in neutropenic leukemic patients. Isr. J. Med. Sci. 1996;32:1089-1092.
Not in our library
328.
Meidani M., Naeini A.E., Rostami M., Sherkat R., Tayeri K. Immunocompromised patients: Review of the most common infections happened in 446 hospitalized patients. J. Res. Med. Sci. 2014;19:S71-S73.
Not in our library
329.
Goodley J.M., Clayton Y.M., Hay R.J. Environmental sampling for aspergilli during building construction on a hospital site. J. Hosp. Infect. 1994;26:27-35.
Not in our library10.1016/0195-6701(94)90076-0
330.
Chazalet V., Debeaupuis J.P., Sarfati J., Lortholary J., Ribaud P., Shah P., Cornet M., Vu Thien H., Gluckman E., Brücker G., et al. Molecular typing of environmental and patient isolates of Aspergillus fumigatus from various hospital settings. J. Clin. Microbiol. 1998;36:1494-1500.
Not in our library10.1128/jcm.36.6.1494-1500.1998
331.
Hospenthal D.R., Kwon-Chung K.J., Bennett J.E. Concentrations of airborne Aspergillus compared to the incidence of invasive aspergillosis: Lack of correlation. Med. Mycol. 1998;36:165-168.
Not in our library10.1080/02681219880000241
332.
Kwon-Chung K.J., Bennett J.E. Medical mycology. Rev. Do Inst. De Med. Trop. De São Paulo. 1992;34:504.
Not in our library10.1590/s0036-46651992000600018
333.
Pennington J. Respiratory Infections: Diagnosis and Management. 1983.
Not in our library
334.
Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision · 2017
No notice
335.
Rajasingham R., Smith R.M., Park B.J., Jarvis J.N., Govender N.P., Chiller T.M., Denning D.W., Loyse A., Boulware D.R. Global burden of disease of HIV-associated cryptococcal meningitis: An updated analysis. Lancet Infect. Dis. 2017;17:873-881.
Not in our library10.1016/s1473-3099(17)30243-8
336.
Knoke M., Schwesinger G. One hundred years ago: The history of cryptococcosis in Greifswald. Medical mycology in the nineteenth century. Mycoses. 1994;37:229-233.
Not in our library10.1111/j.1439-0507.1994.tb00418.x
337.
Casadevall A., Perfect J.R. Cryptococcus Neoformans. 1998;Volume 595.
Not in our library
338.
Maziarz E.K., Perfect J.R. Cryptococcosis. Infect. Dis. Clin. N. Am. 2016;30:179-206.
Not in our library10.1016/j.idc.2015.10.006
339.
Badicut I., Paraschiv S., Borcan A., Tălăpan D., Dorobat O. Risk factors in HIV/AIDS patients with cryptococcal meningitis. BMC Infect. Dis. 2014;14:P29.
Not in our library10.1186/1471-2334-14-s4-p29
340.
Revie N.M., Iyer K.R., Robbins N., Cowen L.E. Antifungal drug resistance: Evolution, mechanisms and impact. Curr. Opin. Microbiol. 2018;45:70-76.
Not in our library10.1016/j.mib.2018.02.005
341.
Antifungal Drugs · 2020
No notice
342.
De Leo M., Braca A., De Tommasi N., Norscia I., Morelli I., Battinelli L., Mazzanti G. Phenolic compounds from Baseonema acuminatum leaves: Isolation and antimicrobial activity. Planta Med. 2004;70:841-846.
Not in our library10.1055/s-2004-827233
343.
Yordanov M., Dimitrova P., Patkar S., Saso L., Ivanovska N. Inhibition of Candida albicans extracellular enzyme activity by selected natural substances and their application in Candida infection. Can. J. Microbiol. 2008;54:435-440.
Not in our library10.1139/w08-029
344.
Dutta S., Kundu A. Macroporous resin-assisted enrichment, characterizations, antioxidant and anticandidal potential of phytochemicals from Trachyspermum ammi. J. Food Biochem. 2022;46:e13847.
Not in our library10.1111/jfbc.13847
345.
Pushkala V.P., Sulekha S.M.P., Mathukumar S., Ragavi B., Sowmiya U. Molecular Docking Analysis of Siddha Formulation Parangipattai Chooranam Against Vaginal Candidiasis. Appl. Biochem. Biotechnol. 2022;194:1039-1050.
Not in our library10.1007/s12010-022-03813-y
346.
Slack A. Parasitic causes of prolonged diarrhoea in travellers—Diagnosis and management. Aust. Fam. Physician. 2012;41:782-786.
Not in our library
347.
El-Dib N.A. Entamoeba histolytica: An Overview. Curr. Trop. Med. Rep. 2017;4:11-20.
Not in our library10.1007/s40475-017-0100-z
348.
Wolfe M.S. Giardiasis. Clin. Microbiol. Rev. 1992;5:93-100.
Not in our library10.1128/cmr.5.1.93
349.
Minetti C., Chalmers R.M., Beeching N.J., Probert C., Lamden K. Giardiasis. BMJ. 2016;355:i5369.
Not in our library10.1136/bmj.i5369
350.
Brun R., Blum J., Chappuis F., Burri C. Human African trypanosomiasis. Lancet. 2010;375:148-159.
Not in our library10.1016/s0140-6736(09)60829-1
351.
Greenwood B. The use of anti-malarial drugs to prevent malaria in the population of malaria-endemic areas. Am. J. Trop. Med. Hyg. 2004;70:1-7.
Not in our library10.4269/ajtmh.2004.70.1
352.
Autino B., Noris A., Russo R., Castelli F. Epidemiology of malaria in endemic areas. Mediterr. J. Hematol. Infect. Dis. 2012;4:e2012060.
Not in our library10.4084/mjhid.2012.060
353.
Abdo M.G., Elamin W.M., Khalil E.A., Mukhtar M.M. Antimony-resistant Leishmania donovaniin eastern Sudan: Incidence and in vitro correlation. East Mediterr. Health J. 2003;9:837-843.
Not in our library10.26719/2003.9.4.837
354.
Majumdar D., Elsayed G.A., Buskas T., Boons G.-J. Synthesis of Proteophosphoglycans of Leishmania major and Leishmania mexicana. J. Org. Chem. 2005;70:1691-1697.
Not in our library10.1021/jo048443z
355.
Leishmaniasis Worldwide and Global Estimates of Its Incidence · 2012
No notice
356.
Calzada F., Alanis A.D., Meckes M., Tapia-Contreras A., Cedillo-Rivera R. In vitro susceptibility of Entamoeba histolytica and Giardia lamblia to some medicinal plants used by the people of Southern Mexico. Phytother. Res. 1998;12:70-72.
Not in our library10.1002/(sici)1099-1573(19980201)12:1<70::aid-ptr189>3.0.co;2-v
357.
Calzada F., Meckes M., Cedillo-Rivera R. Antiamoebic and antigiardial activity of plant flavonoids. Planta Med. 1999;65:78-80.
Not in our library10.1055/s-2006-960445
358.
Meckes M., Calzada F., Tapia-Contreras A., Cedillo-Rivera R. Antiprotozoal properties of Helianthemum glomeratum. Phytother. Res. 1999;13:102-105.
Not in our library10.1002/(sici)1099-1573(199903)13:2<102::aid-ptr408>3.0.co;2-#
359.
Scio E., Ribeiro A., Alves T.M., Romanha A.J., Dias de Souza Filho J., Cordell G.A., Zani C.L. Diterpenes from Alomia myriadenia (Asteraceae) with cytotoxic and trypanocidal activity. Phytochemistry. 2003;64:1125-1131.
Not in our library10.1016/s0031-9422(03)00529-6
360.
Muzitano M.F., Tinoco L.W., Guette C., Kaiser C.R., Rossi-Bergmann B., Costa S.S. The antileishmanial activity assessment of unusual flavonoids from Kalanchoe pinnata. Phytochemistry. 2006;67:2071-2077.
Not in our library10.1016/j.phytochem.2006.06.027
361.
de Monbrison F., Maitrejean M., Latour C., Bugnazet F., Peyron F., Barron D., Picot S. In vitro antimalarial activity of flavonoid derivatives dehydrosilybin and 8-(1;1)-DMA-kaempferide. Acta Trop. 2006;97:102-107.
Not in our library10.1016/j.actatropica.2005.09.004
362.
Cai S., Risinger A.L., Nair S., Peng J., Anderson T.J., Du L., Powell D.R., Mooberry S.L., Cichewicz R.H. Identification of Compounds with Efficacy against Malaria Parasites from Common North American Plants. J. Nat. Prod. 2016;79:490-498.
Not in our library10.1021/acs.jnatprod.5b00874
363.
Pérez-González M.Z., Gutiérrez-Rebolledo G.A., Yépez-Mulia L., Rojas-Tomé I.S., Luna-Herrera J., Jiménez-Arellanes M.A. Antiprotozoal, antimycobacterial, and anti-inflammatory evaluation of Cnidoscolus chayamansa (Mc Vaugh) extract and the isolated compounds. Biomed Pharmacother. 2017;89:89-97.
Not in our library10.1016/j.biopha.2017.02.021
364.
Araújo M.V., Queiroz A.C., Silva J.F.M., Silva A.E., Silva J.K.S., Silva G.R., Silva E.C.O., Souza S.T., Fonseca E.J.S., Camara C.A., et al. Flavonoids induce cell death in Leishmania amazonensis: In vitro characterization by flow cytometry and Raman spectroscopy. Analyst. 2019;144:5232-5244.
Not in our library10.1039/c9an00948e
365.
Alotaibi A., Ebiloma G.U., Williams R., Alfayez I.A., Natto M.J., Alenezi S., Siheri W., AlQarni M., Igoli J.O., Fearnley J., et al. Activity of Compounds from Temperate Propolis against Trypanosoma brucei and Leishmania mexicana. Molecules. 2021;26:3912.
Not in our library10.3390/molecules26133912
366.
Abdallah R.M., Hammoda H.M., Radwan M.M., El-Gazzar N.S., Wanas A.S., ElSohly M.A., El-Demellawy M.A., Abdel-Rahman N.M., Sallam S.M. Phytochemical and pharmacological appraisal of the aerial parts of Lotus corniculatus L. growing in Egypt. Nat. Prod. Res. 2021;35:5914-5917.
Not in our library10.1080/14786419.2020.1802273
367.
Martínez-Castillo M., Pacheco-Yepez J., Flores-Huerta N., Guzmán-Téllez P., Jarillo-Luna R.A., Cárdenas-Jaramillo L.M., Campos-Rodríguez R., Shibayama M. Flavonoids as a Natural Treatment Against Entamoeba histolytica. Front. Cell Infect. Microbiol. 2018;8:209.
Not in our library10.3389/fcimb.2018.00209
368.
The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases · 2010
No notice
369.
Desquesnes M., Dia M.L. Mechanical transmission of Trypanosoma congolense in cattle by the African tabanid Atylotus agrestis. Exp. Parasitol. 2003;105:226-231.
Not in our library10.1016/j.exppara.2003.12.014
370.
Desquesnes M., Dia M.L. Trypanosoma vivax: Mechanical transmission in cattle by one of the most common African tabanids, Atylotus agrestis. Exp. Parasitol. 2003;103:35-43.
Not in our library10.1016/s0014-4894(03)00067-5
371.
Do Cryptic Reservoirs Threaten Gambiense-Sleeping Sickness Elimination? · 2018
No notice
372.
Bouteille B., Oukem O., Bisser S., Dumas M. Treatment perspectives for human African trypanosomiasis. Fundam. Clin. Pharmacol. 2003;17:171-181.
Not in our library10.1046/j.1472-8206.2003.00167.x
373.
Gao J.M., Qian Z.Y., Hide G., Lai D.H., Lun Z.R., Wu Z.D. Human African trypanosomiasis: The current situation in endemic regions and the risks for non-endemic regions from imported cases. Parasitology. 2020;147:922-931.
Not in our library10.1017/s0031182020000645
374.
Baker N., de Koning H.P., Mäser P., Horn D. Drug resistance in African trypanosomiasis: The melarsoprol and pentamidine story. Trends Parasitol. 2013;29:110-118.
Not in our library10.1016/j.pt.2012.12.005
375.
Calzada F., Cedillo-Rivera R., Mata R. Antiprotozoal activity of the constituents of Conyza filaginoides. J. Nat. Prod. 2001;64:671-673.
Not in our library10.1021/np000442o
376.
Kozykeyeva R.A., Datkhayev U.M., Srivedavyasasri R., Ajayi T.O., Patsayev A.K., Kozykeyeva R.A., Ross S.A. Isolation of Chemical Compounds and Essential Oil from Agrimonia asiatica Juz. and Their Antimicrobial and Antiplasmodial Activities. Sci. World J. 2020;2020:7821310.
Not in our library10.1155/2020/7821310
377.
Heredia Díaz Y., Tuenter E., Garcia-Díaz J., Ochoa Pacheco A., Cos P., Pieters L., Escalona Arranz J.C. Novel flavonol-3-O-methylethers from Zanthoxylum pistaciifolium Griseb. (Rutaceae). Nat. Prod. Res. 2021;36:4869-4878.
Not in our library10.1080/14786419.2021.1906240
378.
Antinori S., Galimberti L., Milazzo L., Corbellino M. Biology of human malaria plasmodia including Plasmodium knowlesi. Mediterr. J. Hematol. Infect. Dis. 2012;4:e2012013.
Not in our library10.4084/mjhid.2012.013
379.
Singh B., Daneshvar C. Human infections and detection of Plasmodium knowlesi. Clin. Microbiol. Rev. 2013;26:165-184.
Not in our library10.1128/cmr.00079-12
380.
Ashley E.A., Pyae Phyo A., Woodrow C.J. Malaria. Lancet. 2018;391:1608-1621.
Not in our library10.1016/s0140-6736(18)30324-6
381.
Vuk I., Rajic Z., Zorc B. Malaria and antimalarial drugs. Farm. Glas. 2008;64:51.
Not in our library
382.
Josling G.A., Llinás M. Sexual development in Plasmodium parasites: Knowing when it’s time to commit. Nat. Rev. Microbiol. 2015;13:573-587.
Not in our library10.1038/nrmicro3519
383.
Cowman A.F., Healer J., Marapana D., Marsh K. Malaria: Biology and Disease. Cell. 2016;167:610-624.
Not in our library10.1016/j.cell.2016.07.055
384.
Castelli F., Tomasoni L.R., Matteelli A. Advances in the treatment of malaria. Mediterr. J. Hematol. Infect. Dis. 2012;4:e2012064.
Not in our library10.4084/mjhid.2012.064
385.
Menard D., Dondorp A. Antimalarial Drug Resistance: A Threat to Malaria Elimination. Cold Spring Harb. Perspect. Med. 2017;7:a025619.
Not in our library10.1101/cshperspect.a025619
386.
Lipan L., Alexandru M., Dedu A., Viaşu A., Piţigoi D., Rafila A. Current state of the epidemiology of malaria in Romania. Bacteriol. Virusol. Parazitol. Epidemiol. 2011;56:25-38.
Not in our library
387.
Rashid M.I., Fareed M.I., Rashid H., Aziz H., Ehsan N., Khalid S., Ghaffar I., Ali R., Gul A., Hakeem K.R., Ozturk M., Hakeem K.R. Flavonoids and Their Biological Secrets. Plant and Human Health, Volume 2: Phytochemistry and Molecular Aspects. 2019;579-605.
Not in our library10.1007/978-3-030-03344-6_24
388.
Ortiz S., Vásquez-Ocmín P.G., Cojean S., Bouzidi C., Michel S., Figadère B., Grougnet R., Boutefnouchet S., Maciuk A. Correlation study on methoxylation pattern of flavonoids and their heme-targeted antiplasmodial activity. Bioorg. Chem. 2020;104:104243.
Not in our library10.1016/j.bioorg.2020.104243
389.
Leishmaniasis: a review · 2017
No notice
390.
Andrade-Narváez F.J., Vargas-González A., Canto-Lara S.B., Damián-Centeno A.G. Clinical picture of cutaneous leishmaniases due to Leishmania (Leishmania) mexicana in the Yucatan peninsula, Mexico. Mem. Inst. Oswaldo Cruz. 2001;96:163-167.
Not in our library10.1590/s0074-02762001000200005
391.
Mann S., Frasca K., Scherrer S., Henao-Martínez A.F., Newman S., Ramanan P., Suarez J.A. A Review of Leishmaniasis: Current Knowledge and Future Directions. Curr. Trop. Med. Rep. 2021;8:121-132.
Not in our library10.1007/s40475-021-00232-7
392.
Periferakis A., Caruntu A., Periferakis A.-T., Scheau A.-E., Badarau I.A., Caruntu C., Scheau C. Availability, Toxicology and Medical Significance of Antimony. Int. J. Environ. Res. Public Health. 2022;19:4669.
Not in our library10.3390/ijerph19084669
393.
Pentavalent Antimonials: New Perspectives for Old Drugs · 2009
No notice
394.
Marques S.A., Merlotto M.R., Ramos P.M., Marques M.E.A. American tegumentary leishmaniasis: Severe side effects of pentavalent antimonial in a patient with chronic renal failure. An. Bras. De Dermatol. 2019;94:355-357.
Not in our library10.1590/abd1806-4841.20198388
395.
Vasarri M., Barletta E., Vinci S., Ramazzotti M., Francesconi A., Manetti F., Degl’Innocenti D. Annona cherimola Miller fruit as a promising candidate against diabetic complications: An in vitro study and preliminary clinical results. Foods. 2020;9:1350.
Not in our library10.3390/foods9101350
396.
Martínez-Solís J., Calzada F., Barbosa E., Valdés M. Antihyperglycemic and antilipidemic properties of a tea infusion of the leaves from Annona cherimola miller on streptozocin-induced type 2 diabetic mice. Molecules. 2021;26:2408.
Not in our library10.3390/molecules26092408
397.
Galani V.J., Patel B.G., Patel N.B. Argyreia speciosa (Linn. f.) sweet: A comprehensive review. Pharmacogn. Rev. 2010;4:172-178.
Not in our library10.4103/0973-7847.70913
398.
Joseph A., Mathew S., Skaria B.P., Sheeja E. Medicinal uses and biological activities of Argyreia speciosa sweet (Hawaiian baby woodrose)-an overview. Indian J. Nat. Prod. Resour. 2011;2:286-291.
Not in our library
399.
Ullah M., Khan M.U., Mahmood A., Malik R.N., Hussain M., Wazir S.M., Daud M., Shinwari Z.K. An ethnobotanical survey of indigenous medicinal plants in Wana district south Waziristan agency, Pakistan. J. Ethnopharmacol. 2013;150:918-924.
Not in our library10.1016/j.jep.2013.09.032
400.
Mali R.G., Mahajan S.G., Mehta A.A. Phcog Rev.: Plant review Rakta Kanchan (Bauhinia variegata): Chemistry traditional and medicinal uses—A review. Pharmacogn. Rev. 2007;1:314-319.
Not in our library
401.
Dhale D. Phytochemical screening and antimicrobial activity of Bauhinia variegata Linn. J. Ecobiotechnol. 2011;3:4-7.
Not in our library
402.
Akinpelu D.A. Antimicrobial activity of Bryophyllum pinnatum leaves. Fitoterapia. 2000;71:193-194.
Not in our library10.1016/s0367-326x(99)00135-5
403.
Kamboj A., Saluja A. Bryophyllum pinnatum (Lam.) Kurz.: Phytochemical and pharmacological profile: A review. Pharmacogn. Rev. 2009;3:364.
Not in our library
404.
Youssef F.S., Ashour M.L., El-Beshbishy H.A., Singab A.N.B., Wink M. Metabolic Profiling of Buddleia indica Leaves using LC/MS and Evidence of their Antioxidant and Hepatoprotective Activity Using Different In Vitro and In Vivo Experimental Models. Antioxidants. 2019;8:412.
Not in our library10.3390/antiox8090412
405.
Yao R.Y., Zou Y.F., Chen X.F. Traditional Use, Pharmacology, Toxicology, and Quality Control of Species in Genus Bupleurum L. Chin. Herb. Med. 2013;5:245-255.
Not in our library10.1016/s1674-6384(13)60036-2
406.
Dang Z., Li Q., Sun S., Wang Y., Lin R., Zhang Y., Dai J., Zheng N. The Medicinal Plant Pair Bupleurum chinense-Scutellaria baicalensis—Metabolomics and Metallomics Analysis in a Model for Alcoholic Liver Injury. Front. Pharmacol. 2019;10:254.
Not in our library10.3389/fphar.2019.00254
407.
Angelica B.C., Maria R.A.V.A., Gabino A.M.G., Patricia S.S.M., Rafael P.P. The traditional medicinal and food uses of four plants in Oaxaca, Mexico. J. Med. Plants Res. 2011;5:3404-3411.
Not in our library
408.
Barbosa E., Calzada F., Campos R. In vivo antigiardial activity of three flavonoids isolated of some medicinal plants used in Mexican traditional medicine for the treatment of diarrhea. J. Ethnopharmacol. 2007;109:552-554.
Not in our library10.1016/j.jep.2006.09.009
409.
Aponte J.C., Vaisberg A.J., Rojas R., Caviedes L., Lewis W.H., Lamas G., Sarasara C., Gilman R.H., Hammond G.B. Isolation of Cytotoxic Metabolites from Targeted Peruvian Amazonian Medicinal Plants. J. Nat. Prod. 2008;71:102-105.
Not in our library10.1021/np070560c
410.
Tetik F., Civelek S., Cakilcioglu U. Traditional uses of some medicinal plants in Malatya (Turkey). J. Ethnopharmacol. 2013;146:331-346.
Not in our library10.1016/j.jep.2012.12.054
411.
Meckes M., Torres J., Calzada F., Rivera J., Camorlinga M., Lemus H., Rodríguez G. Antibacterial Properties of Helianthemum glomeratum, a Plant Used in Maya Traditional Medicine to Treat Diarrhoea. Phytother. Res. 1997;11:128-131.
Not in our library10.1002/(sici)1099-1573(199703)11:2<128::aid-ptr55>3.0.co;2-n
412.
Yang X., Summerhurst D.K., Koval S.F., Ficker C., Smith M.L., Bernards M.A. Isolation of an antimicrobial compound from Impatiens balsamina L. using bioassay-guided fractionation. Phytother. Res. 2001;15:676-680.
Not in our library10.1002/ptr.906
413.
Li Q., Cao J., Yuan W., Li M., Yang L., Sun Y., Wang X., Zhao Y. New triterpene saponins from flowers of Impatiens balsamina L. and their anti-hepatic fibrosis activity. J. Funct. Foods. 2017;33:188-193.
Not in our library10.1016/j.jff.2017.03.033
414.
Costa S.S., Muzitano M.F., Camargo L.M.M., Coutinho M.A.S. Therapeutic Potential of Kalanchoe Species: Flavonoids and other Secondary Metabolites. Nat. Prod. Commun. 2008;3:1934578X0800301236.
Not in our library10.1177/1934578x0800301236
415.
Abdullah N., Hosseinpour Chermahini D.S., Chua L.S., Sarmidi M. Labisia pumila: A review on its traditional, phytochemical and biological uses. World Appl. Sci. J. 2013;27:1297-1306.
Not in our library10.5829/idosi.wasj.2013.27.10.1391
416.
Zakaria A.A., Noor M.H.M., Ahmad H., Hassim H.A., Mazlan M., Latip M.Q.A. A Review on Therapeutic Effects of Labisia pumila on Female Reproductive Diseases. Biomed Res. Int. 2021;2021:9928199.
Not in our library10.1155/2021/9928199
417.
Zmeeva O., Kolomiets N., Abramets N., Bondarchuk R. Lotus corniculatus L. is a perspective species of the genus Lotus L. 2017;5-14.
Not in our library
418.
Gürağaç Dereli F.T., Khan H., Sobarzo-Sánchez E., Akkol E.K. Antidepressant Potential of Lotus corniculatus L. subsp. corniculatus: An Ethnobotany Based Approach. Molecules. 2020;25:1299.
Not in our library10.3390/molecules25061299
419.
Germano M., Sanogo R., Costa C., Fulco R., D’angelo V., Torre E., Viscomi M., De Pasquale R. Hepatoprotective properties in the rat of Mitracarpus scaber (Rubiaceae). J. Pharm. Pharmacol. 1999;51:729-734.
Not in our library10.1211/0022357991772871
420.
Meite S., N’guessan J., Bahi C., Yapi H., Djaman A., Guina F.G. Antidiarrheal activity of the ethyl acetate extract of Morinda morindoides in rats. Trop. J. Pharm. Res. 2009;8:201-207.
Not in our library10.4314/tjpr.v8i3.44533
421.
Mohammed A., Tam D.N.H., Vu T.L.H., Tieu T.M., Elfaituri M.K., Trinh N.N., Sagheir E.A., Tran L., Loc T.T.H., Low S.K., et al. Morinda morindoides: A systematic review of its therapeutic activities. South Afr. J. Bot. 2020;131:93-103.
Not in our library10.1016/j.sajb.2020.01.045
422.
Suriyaphan O. Nutrition, health benefits and applications of Pluchea indica (L.) Less leaves. Mahidol Univ. J. Pharm. Sci. 2014;41:1-10.
Not in our library
423.
Vongsak B., Kongkiatpaiboon S., Jaisamut S., Konsap K. Comparison of active constituents, antioxidant capacity, and α-glucosidase inhibition in Pluchea indica leaf extracts at different maturity stages. Food Biosci. 2018;25:68-73.
Not in our library10.1016/j.fbio.2018.08.006
424.
Historical Aspects of Propolis Research in Modern Times · 2013
No notice
425.
Rusanov K., Kovacheva N., Vosman B., Zhang L., Rajapakse S., Atanassov A., Atanassov I. Microsatellite analysis of Rosa damascena Mill. accessions reveals genetic similarity between genotypes used for rose oil production and old Damask rose varieties. Theor. Appl. Genet. 2005;111:804-809.
Not in our library10.1007/s00122-005-2066-9
426.
Dalfardi B., Heydari M., Golzari S.E.J., Mahmoudi Nezhad G.S., Hashempur M.H. Al-Baghdadi’s description of venous blood circulation. Int. J. Cardiol. 2014;174:209-210.
Not in our library10.1016/j.ijcard.2014.03.199
427.
Mahboubi M. Rosa damascena as holy ancient herb with novel applications. J. Tradit. Complement. Med. 2016;6:10-16.
Not in our library10.1016/j.jtcme.2015.09.005
428.
Nayebi N., Khalili N., Kamalinejad M., Emtiazy M. A systematic review of the efficacy and safety of Rosa damascena Mill. with an overview on its phytopharmacological properties. Complement. Ther. Med. 2017;34:129-140.
Not in our library10.1016/j.ctim.2017.08.014
429.
Vlachou G., Papafotiou M., Akoumianaki A., Bertsouklis K.F. Propagation of Scabiosa hymettia (Boiss. & Spruner) by stem cuttings. Acta Hortic. 2019;1242:763-766.
Not in our library
430.
Siqueira S., dos Santos Falcão-Silva V., de Fátima Agra M., Dariva C., de Siqueira-Júnior J.P., Fonseca M.J.V. Biological activities of Solanum paludosum Moric. extracts obtained by maceration and supercritical fluid extraction. J. Supercrit. Fluids. 2011;58:391-397.
Not in our library10.1016/j.supflu.2011.06.011
431.
Syzygium aromaticum L. (Myrtaceae): Traditional Uses, Bioactive Chemical Constituents, Pharmacological and Toxicological Activities · 2020
No notice
432.
Ngbolua K., Tshibangu D., Mpiana P., Mihigo S., Mavakala B., Ashande M., Muanyishay L. Anti-sickling and antibacterial activities of Some Extracts from Gardenia ternifolia subsp. jovis-tonantis (Welw.) Verdc.(Rubiaceae) and Uapaca heudelotii Baill.(Phyllanthaceae). Infection. 2015;4:6.
Not in our library10.9734/jamps/2015/13427
433.
Asante-Kwatia E., Gyimah L., Mensah A.Y., Sarpong K., Obeng A.K. Authentication and quality control of Uapaca heudelotii Baill.—An investigation of pharmacognostic, phytochemical and physicochemical properties of its leaves and stem bark. Plant Sci. Today. 2022;9:477-485.
Not in our library10.14719/pst.1476
434.
Baviloni P.D., dos Santos M.P., Aiko G.M., de Lima Reis S.R., Latorraca M.Q., da Silva V.C., Dall’Oglio E.L., de Sousa Júnior P.T., Lopes C.F., Baviera A.M., et al. Mechanism of anti-hyperglycemic action of Vatairea macrocarpa (Leguminosae): Investigation in peripheral tissues. J. Ethnopharmacol. 2010;131:135-139.
Not in our library10.1016/j.jep.2010.06.015
435.
Patel S. Yucca: A medicinally significant genus with manifold therapeutic attributes. Nat. Prod. Bioprospecting. 2012;2:231-234.
Not in our library10.1007/s13659-012-0090-4
436.
Andrews C.M., Wyne K., Svenson J.E. The use of traditional and complementary medicine for diabetes in rural Guatemala. J. Health Care Poor Underserved. 2018;29:1188-1208.
Not in our library10.1353/hpu.2018.0092
437.
Zhu Y.-P., Woerdenbag H.J. Traditional Chinese herbal medicine. Pharm. World Sci. 1995;17:103-112.
Not in our library10.1007/bf01872386
438.
Gu S., Pei J. Innovating Chinese Herbal Medicine: From Traditional Health Practice to Scientific Drug Discovery. Front. Pharmacol. 2017;8:381.
Not in our library10.3389/fphar.2017.00381
439.
Gongwang L. Chinese Herbal Medicine. 1999.
Not in our library
440.
Bensky D., Barolet R. Chinese Herbal Medicine—Formulas & Strategies. 1990.
Not in our library
441.
Radix Bupleuri : A Review of Traditional Uses, Botany, Phytochemistry, Pharmacology, and Toxicology · 2017
No notice
442.
Cheng Y.L., Chang W.L., Lee S.C., Liu Y.G., Lin H.C., Chen C.J., Yen C.Y., Yu D.S., Lin S.Z., Harn H.J. Acetone extract of Bupleurum scorzonerifolium inhibits proliferation of A549 human lung cancer cells via inducing apoptosis and suppressing telomerase activity. Life Sci. 2003;73:2383-2394.
Not in our library10.1016/s0024-3205(03)00648-9
443.
Chiang L.C., Ng L.T., Liu L.T., Shieh D.E., Lin C.C. Cytotoxicity and anti-hepatitis B virus activities of saikosaponins from Bupleurum species. Planta Med. 2003;69:705-709.
Not in our library10.1055/s-2003-42797
444.
Xie Y., Lu W., Cao S., Jiang X., Yin M., Tang W. Preparation of bupleurum nasal spray and evaluation on its safety and efficacy. Chem. Pharm. Bull. 2006;54:48-53.
Not in our library10.1248/cpb.54.48
445.
Xie J.Y., Di H.Y., Li H., Cheng X.Q., Zhang Y.Y., Chen D.F. Bupleurum chinense DC polysaccharides attenuates lipopolysaccharide-induced acute lung injury in mice. Phytomedicine. 2012;19:130-137.
Not in our library10.1016/j.phymed.2011.08.057
446.
Zhu J., Luo C., Wang P., He Q., Zhou J., Peng H. Saikosaponin A mediates the inflammatory response by inhibiting the MAPK and NF-κB pathways in LPS-stimulated RAW 264.7 cells. Exp. Ther. Med. 2013;5:1345-1350.
Not in our library10.3892/etm.2013.988
447.
Li Z.Y., Sun H.M., Xing J., Qin X.M., Du G.H. Chemical and biological comparison of raw and vinegar-baked Radix Bupleuri. J. Ethnopharmacol. 2015;165:20-28.
Not in our library10.1016/j.jep.2015.02.024
448.
He C., Chen J., Liu J., Li Y., Zhou Y., Mao T., Li Z., Qin X., Jin S. Geranium wilfordii maxim.: A review of its traditional uses, phytochemistry, pharmacology, quality control and toxicology. J. Ethnopharmacol. 2022;285:114907.
Not in our library10.1016/j.jep.2021.114907
449.
Huang M., Yao P.W., Chang M.D., Ng S.K., Yu C.H., Zhang Y.F., Wen M.L., Yang X.Y., Lai Y.K. Identification of anti-inflammatory fractions of Geranium wilfordii using tumor necrosis factor-alpha as a drug target on Herbochip®—An array-based high throughput screening platform. BMC Complement. Altern. Med. 2015;15:146.
Not in our library10.1186/s12906-015-0665-9
450.
Tilikidis A. Chinese Herbal Therapy—Herbs and Formulas. 2017.
Not in our library
451.
Amiri M.S., Joharchi M.R., Nadaf M., Nasseh Y. Ethnobotanical knowledge of Astragalus spp.: The world’s largest genus of vascular plants. Avicenna J. Phytomed. 2020;10:128-142.
Not in our library
452.
Lev E., Amar Z. Ethnopharmacological survey of traditional drugs sold in the Kingdom of Jordan. J. Ethnopharmacol. 2002;82:131-145.
Not in our library10.1016/s0378-8741(02)00182-4
453.
Chaudhary L.B., Rana T.S., Anand K.K. Current status of the systematics of Astragalus L.(Fabaceae) with special reference to the Himalayan species in India. Taiwania. 2008;53:338-355.
Not in our library
454.
Kumar G.P., Gupta S., Murugan M.P., Bala Singh S. Ethnobotanical studies of Nubra Valley-A cold arid zone of Himalaya. Ethnobot. Leafl. 2009;2009:9.
Not in our library
455.
Ghasemi Pirbalouti A., Momeni M., Bahmani M. Ethnobotanical study of medicinal plants used by Kurd tribe in Dehloran and Abdanan Districts, Ilam Province, Iran. Afr. J. Tradit. Complement. Altern. Med. 2013;10:368-385.
Not in our library10.4314/ajtcam.v10i2.24
456.
Dexter D.F., Martin K., Travis L. Prehistoric plant use at beaver creek rock shelter, Southwestern Montana, USA. Ethnobot. Res. Appl. 2014;12:355-384.
Not in our library10.17348/era.12.0.355-384
457.
Chermat S., Gharzouli R. Ethnobotanical study of medicinal flora in the North East of Algeria-An empirical knowledge in Djebel Zdimm (Setif). J. Mater. Sci. Eng. 2015;5:50-59.
Not in our library
458.
Lakhdari W., Dehliz A., Acheuk F., Mlik R., Hammi H., DOUMANDJI-MITICHE B., Gheriani S., Berrekbia M., Guermit K., Chergui S. Ethnobotanical study of some plants used in traditional medicine in the region of Oued Righ (Algerian Sahara). J. Med. Plants. 2016;4:204-211.
Not in our library
459.
Sun L., Liao L., Wang B. Potential Antinociceptive Effects of Chinese Propolis and Identification on Its Active Compounds. J. Immunol. Res. 2018;2018:5429543.
Not in our library10.1155/2018/5429543
460.
Zhu W., Chen M., Shou Q., Li Y., Hu F. Biological activities of chinese propolis and brazilian propolis on streptozotocin-induced type 1 diabetes mellitus in rats. Evid. -Based Complement. Altern. Med. 2011;2011:468529.
Not in our library10.1093/ecam/neq025
461.
Periferakis A., Bolocan A., Ion D. A Review of Innovation in Medicine. Technol. Innov. Life Sci. 2022;1:42-48.
Not in our library10.56051/tils.v1i1.7
462.
Newman D.J., Cragg G.M. Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019. J. Nat. Prod. 2020;83:770-803.
Not in our library10.1021/acs.jnatprod.9b01285
463.
Scheau C., Mihai L., Bădărău I., Caruntu C. Emerging applications of some important natural compounds in the field of oncology. Farmacia. 2020;68:984-991.
Not in our library10.31925/farmacia.2020.6.4
464.
Plant-Derived Anticancer Compounds as New Perspectives in Drug Discovery and Alternative Therapy · 2021
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.